CN100520793C - 影响物质生产的代谢流量的测定方法 - Google Patents
影响物质生产的代谢流量的测定方法 Download PDFInfo
- Publication number
- CN100520793C CN100520793C CNB2004800272636A CN200480027263A CN100520793C CN 100520793 C CN100520793 C CN 100520793C CN B2004800272636 A CNB2004800272636 A CN B2004800272636A CN 200480027263 A CN200480027263 A CN 200480027263A CN 100520793 C CN100520793 C CN 100520793C
- Authority
- CN
- China
- Prior art keywords
- metabolic flux
- arg
- metabolic
- glu
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000002503 metabolic effect Effects 0.000 title claims abstract description 97
- 230000004907 flux Effects 0.000 title claims abstract description 94
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims description 68
- 239000000463 material Substances 0.000 title claims description 63
- 239000011159 matrix material Substances 0.000 claims abstract description 33
- 238000009826 distribution Methods 0.000 claims abstract description 18
- 238000005842 biochemical reaction Methods 0.000 claims abstract description 15
- 239000000758 substrate Substances 0.000 claims abstract description 12
- 238000007619 statistical method Methods 0.000 claims abstract description 10
- 230000001580 bacterial effect Effects 0.000 claims description 78
- 235000015097 nutrients Nutrition 0.000 claims description 35
- 239000001963 growth medium Substances 0.000 claims description 30
- 150000007524 organic acids Chemical class 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 150000007523 nucleic acids Chemical class 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 230000000875 corresponding effect Effects 0.000 claims description 14
- 238000004458 analytical method Methods 0.000 claims description 9
- 230000004060 metabolic process Effects 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 238000004364 calculation method Methods 0.000 claims description 6
- 238000012417 linear regression Methods 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 6
- 238000009825 accumulation Methods 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 46
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 44
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 38
- 239000012634 fragment Substances 0.000 description 38
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 32
- 239000004472 Lysine Substances 0.000 description 32
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 30
- 108091034117 Oligonucleotide Proteins 0.000 description 29
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 29
- 101100182965 Escherichia coli (strain K12) maeA gene Proteins 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 28
- 239000002609 medium Substances 0.000 description 27
- 239000000047 product Substances 0.000 description 27
- 239000013612 plasmid Substances 0.000 description 25
- 238000003556 assay Methods 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- 235000018977 lysine Nutrition 0.000 description 22
- 239000004473 Threonine Substances 0.000 description 21
- 229960002898 threonine Drugs 0.000 description 21
- 239000002028 Biomass Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 102100037579 D-3-phosphoglycerate dehydrogenase Human genes 0.000 description 17
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 17
- DTBNBXWJWCWCIK-UHFFFAOYSA-N Phosphoenolpyruvic acid Natural products OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 16
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 16
- 241000701959 Escherichia virus Lambda Species 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 229910002092 carbon dioxide Inorganic materials 0.000 description 15
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 14
- 108020003285 Isocitrate lyase Proteins 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 230000002950 deficient Effects 0.000 description 14
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 230000029087 digestion Effects 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 102000004594 DNA Polymerase I Human genes 0.000 description 12
- 108010017826 DNA Polymerase I Proteins 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 11
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 11
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 10
- 235000019766 L-Lysine Nutrition 0.000 description 10
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 10
- 229960000723 ampicillin Drugs 0.000 description 10
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 10
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 10
- 238000012408 PCR amplification Methods 0.000 description 9
- 229940041514 candida albicans extract Drugs 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 238000006062 fragmentation reaction Methods 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 239000012138 yeast extract Substances 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 108010068380 arginylarginine Proteins 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 8
- 241000282326 Felis catus Species 0.000 description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 7
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 6
- 229960002064 kanamycin sulfate Drugs 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 6
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 108010055991 BglII endonuclease Proteins 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 5
- 239000013076 target substance Substances 0.000 description 5
- 239000012137 tryptone Substances 0.000 description 5
- PQGCEDQWHSBAJP-TXICZTDVSA-N 5-O-phosphono-alpha-D-ribofuranosyl diphosphate Chemical compound O[C@H]1[C@@H](O)[C@@H](O[P@](O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O PQGCEDQWHSBAJP-TXICZTDVSA-N 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- LPAJOCKCPRZEAG-MNXVOIDGSA-N Lys-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCCN LPAJOCKCPRZEAG-MNXVOIDGSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 108010093581 aspartyl-proline Proteins 0.000 description 4
- 101150055766 cat gene Proteins 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 108010049041 glutamylalanine Proteins 0.000 description 4
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229940107700 pyruvic acid Drugs 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 108010061238 threonyl-glycine Proteins 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 101800000628 PDH precursor-related peptide Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- RNBGYGVWRKECFJ-ARQDHWQXSA-N beta-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ARQDHWQXSA-N 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 108010045673 endodeoxyribonuclease XBAI Proteins 0.000 description 3
- 150000002085 enols Chemical class 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- SADYNMDJGAWAEW-JKQORVJESA-N (2s)-2-[[(2s)-3-carboxy-2-[[(2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN SADYNMDJGAWAEW-JKQORVJESA-N 0.000 description 2
- AOXKZRNFFMKAOV-JYJNAYRXSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]hexanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)NC(=O)CN)C1=CN=CN1 AOXKZRNFFMKAOV-JYJNAYRXSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102100022734 Acyl carrier protein, mitochondrial Human genes 0.000 description 2
- VBDMWOKJZDCFJM-FXQIFTODSA-N Ala-Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N VBDMWOKJZDCFJM-FXQIFTODSA-N 0.000 description 2
- QDRGPQWIVZNJQD-CIUDSAMLSA-N Ala-Arg-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O QDRGPQWIVZNJQD-CIUDSAMLSA-N 0.000 description 2
- LWUWMHIOBPTZBA-DCAQKATOSA-N Ala-Arg-Lys Chemical compound NC(=N)NCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O LWUWMHIOBPTZBA-DCAQKATOSA-N 0.000 description 2
- OQCPATDFWYYDDX-HGNGGELXSA-N Ala-Gln-His Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O OQCPATDFWYYDDX-HGNGGELXSA-N 0.000 description 2
- PNALXAODQKTNLV-JBDRJPRFSA-N Ala-Ile-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O PNALXAODQKTNLV-JBDRJPRFSA-N 0.000 description 2
- NYDBKUNVSALYPX-NAKRPEOUSA-N Ala-Ile-Arg Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NYDBKUNVSALYPX-NAKRPEOUSA-N 0.000 description 2
- OKIKVSXTXVVFDV-MMWGEVLESA-N Ala-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N OKIKVSXTXVVFDV-MMWGEVLESA-N 0.000 description 2
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 2
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 2
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 2
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- UXJCMQFPDWCHKX-DCAQKATOSA-N Arg-Arg-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UXJCMQFPDWCHKX-DCAQKATOSA-N 0.000 description 2
- OVVUNXXROOFSIM-SDDRHHMPSA-N Arg-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O OVVUNXXROOFSIM-SDDRHHMPSA-N 0.000 description 2
- UISQLSIBJKEJSS-GUBZILKMSA-N Arg-Arg-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(O)=O UISQLSIBJKEJSS-GUBZILKMSA-N 0.000 description 2
- NONSEUUPKITYQT-BQBZGAKWSA-N Arg-Asn-Gly Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)N)CN=C(N)N NONSEUUPKITYQT-BQBZGAKWSA-N 0.000 description 2
- XVLLUZMFSAYKJV-GUBZILKMSA-N Arg-Asp-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XVLLUZMFSAYKJV-GUBZILKMSA-N 0.000 description 2
- NTAZNGWBXRVEDJ-FXQIFTODSA-N Arg-Asp-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NTAZNGWBXRVEDJ-FXQIFTODSA-N 0.000 description 2
- OTCJMMRQBVDQRK-DCAQKATOSA-N Arg-Asp-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O OTCJMMRQBVDQRK-DCAQKATOSA-N 0.000 description 2
- NYZGVTGOMPHSJW-CIUDSAMLSA-N Arg-Glu-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N NYZGVTGOMPHSJW-CIUDSAMLSA-N 0.000 description 2
- JAYIQMNQDMOBFY-KKUMJFAQSA-N Arg-Glu-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JAYIQMNQDMOBFY-KKUMJFAQSA-N 0.000 description 2
- HQIZDMIGUJOSNI-IUCAKERBSA-N Arg-Gly-Arg Chemical compound N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQIZDMIGUJOSNI-IUCAKERBSA-N 0.000 description 2
- RFXXUWGNVRJTNQ-QXEWZRGKSA-N Arg-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N RFXXUWGNVRJTNQ-QXEWZRGKSA-N 0.000 description 2
- OQCWXQJLCDPRHV-UWVGGRQHSA-N Arg-Gly-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O OQCWXQJLCDPRHV-UWVGGRQHSA-N 0.000 description 2
- UBCPNBUIQNMDNH-NAKRPEOUSA-N Arg-Ile-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O UBCPNBUIQNMDNH-NAKRPEOUSA-N 0.000 description 2
- OFIYLHVAAJYRBC-HJWJTTGWSA-N Arg-Ile-Phe Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O OFIYLHVAAJYRBC-HJWJTTGWSA-N 0.000 description 2
- KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 description 2
- ZCSHHTFOZULVLN-SZMVWBNQSA-N Arg-Trp-Val Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N)=CNC2=C1 ZCSHHTFOZULVLN-SZMVWBNQSA-N 0.000 description 2
- VYZBPPBKFCHCIS-WPRPVWTQSA-N Arg-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N VYZBPPBKFCHCIS-WPRPVWTQSA-N 0.000 description 2
- JJGRJMKUOYXZRA-LPEHRKFASA-N Asn-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N)C(=O)O JJGRJMKUOYXZRA-LPEHRKFASA-N 0.000 description 2
- PCKRJVZAQZWNKM-WHFBIAKZSA-N Asn-Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O PCKRJVZAQZWNKM-WHFBIAKZSA-N 0.000 description 2
- UDSVWSUXKYXSTR-QWRGUYRKSA-N Asn-Gly-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UDSVWSUXKYXSTR-QWRGUYRKSA-N 0.000 description 2
- XVBDDUPJVQXDSI-PEFMBERDSA-N Asn-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N XVBDDUPJVQXDSI-PEFMBERDSA-N 0.000 description 2
- XPGVTUBABLRGHY-BIIVOSGPSA-N Asp-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N XPGVTUBABLRGHY-BIIVOSGPSA-N 0.000 description 2
- ILJQISGMGXRZQQ-IHRRRGAJSA-N Asp-Arg-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ILJQISGMGXRZQQ-IHRRRGAJSA-N 0.000 description 2
- KNMRXHIAVXHCLW-ZLUOBGJFSA-N Asp-Asn-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N)C(=O)O KNMRXHIAVXHCLW-ZLUOBGJFSA-N 0.000 description 2
- AITKTFCQOBRJTG-CIUDSAMLSA-N Asp-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N AITKTFCQOBRJTG-CIUDSAMLSA-N 0.000 description 2
- YVHGKXAOSVBGJV-CIUDSAMLSA-N Asp-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N YVHGKXAOSVBGJV-CIUDSAMLSA-N 0.000 description 2
- YWLDTBBUHZJQHW-KKUMJFAQSA-N Asp-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N YWLDTBBUHZJQHW-KKUMJFAQSA-N 0.000 description 2
- 108010072454 CTGCAG-specific type II deoxyribonucleases Proteins 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 241000186226 Corynebacterium glutamicum Species 0.000 description 2
- 241000701867 Enterobacteria phage T7 Species 0.000 description 2
- 241000660147 Escherichia coli str. K-12 substr. MG1655 Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010072863 GACGTC-specific type II deoxyribonucleases Proteins 0.000 description 2
- ITZWDGBYBPUZRG-KBIXCLLPSA-N Gln-Ile-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O ITZWDGBYBPUZRG-KBIXCLLPSA-N 0.000 description 2
- MTAOBYXRYJZRGQ-WDSKDSINSA-N Glu-Gly-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MTAOBYXRYJZRGQ-WDSKDSINSA-N 0.000 description 2
- CAVMESABQIKFKT-IUCAKERBSA-N Glu-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N CAVMESABQIKFKT-IUCAKERBSA-N 0.000 description 2
- YKBUCXNNBYZYAY-MNXVOIDGSA-N Glu-Lys-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YKBUCXNNBYZYAY-MNXVOIDGSA-N 0.000 description 2
- SOEPMWQCTJITPZ-SRVKXCTJSA-N Glu-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N SOEPMWQCTJITPZ-SRVKXCTJSA-N 0.000 description 2
- BPLNJYHNAJVLRT-ACZMJKKPSA-N Glu-Ser-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O BPLNJYHNAJVLRT-ACZMJKKPSA-N 0.000 description 2
- RGJKYNUINKGPJN-RWRJDSDZSA-N Glu-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)O)N RGJKYNUINKGPJN-RWRJDSDZSA-N 0.000 description 2
- YQAQQKPWFOBSMU-WDCWCFNPSA-N Glu-Thr-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O YQAQQKPWFOBSMU-WDCWCFNPSA-N 0.000 description 2
- RZMXBFUSQNLEQF-QEJZJMRPSA-N Glu-Trp-Asn Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N RZMXBFUSQNLEQF-QEJZJMRPSA-N 0.000 description 2
- VJVAQZYGLMJPTK-QEJZJMRPSA-N Glu-Trp-Asp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N VJVAQZYGLMJPTK-QEJZJMRPSA-N 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 description 2
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 2
- VBOBNHSVQKKTOT-YUMQZZPRSA-N Gly-Lys-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O VBOBNHSVQKKTOT-YUMQZZPRSA-N 0.000 description 2
- FNXSYBOHALPRHV-ONGXEEELSA-N Gly-Val-Lys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN FNXSYBOHALPRHV-ONGXEEELSA-N 0.000 description 2
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 2
- IMCHNUANCIGUKS-SRVKXCTJSA-N His-Glu-Arg Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IMCHNUANCIGUKS-SRVKXCTJSA-N 0.000 description 2
- FIMNVXRZGUAGBI-AVGNSLFASA-N His-Glu-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FIMNVXRZGUAGBI-AVGNSLFASA-N 0.000 description 2
- VTZYMXGGXOFBMX-DJFWLOJKSA-N His-Ile-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O VTZYMXGGXOFBMX-DJFWLOJKSA-N 0.000 description 2
- CKRJBQJIGOEKMC-SRVKXCTJSA-N His-Lys-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O CKRJBQJIGOEKMC-SRVKXCTJSA-N 0.000 description 2
- RXKFKJVJVHLRIE-XIRDDKMYSA-N His-Ser-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CN=CN3)N RXKFKJVJVHLRIE-XIRDDKMYSA-N 0.000 description 2
- 101000678845 Homo sapiens Acyl carrier protein, mitochondrial Proteins 0.000 description 2
- HDODQNPMSHDXJT-GHCJXIJMSA-N Ile-Asn-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O HDODQNPMSHDXJT-GHCJXIJMSA-N 0.000 description 2
- IDAHFEPYTJJZFD-PEFMBERDSA-N Ile-Asp-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N IDAHFEPYTJJZFD-PEFMBERDSA-N 0.000 description 2
- ZDNORQNHCJUVOV-KBIXCLLPSA-N Ile-Gln-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O ZDNORQNHCJUVOV-KBIXCLLPSA-N 0.000 description 2
- UBHUJPVCJHPSEU-GRLWGSQLSA-N Ile-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N UBHUJPVCJHPSEU-GRLWGSQLSA-N 0.000 description 2
- QQVXERGIFIRCGW-NAKRPEOUSA-N Ile-Ser-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)O)N QQVXERGIFIRCGW-NAKRPEOUSA-N 0.000 description 2
- COWHUQXTSYTKQC-RWRJDSDZSA-N Ile-Thr-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N COWHUQXTSYTKQC-RWRJDSDZSA-N 0.000 description 2
- NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 2
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 2
- HFBCHNRFRYLZNV-GUBZILKMSA-N Leu-Glu-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HFBCHNRFRYLZNV-GUBZILKMSA-N 0.000 description 2
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 2
- USLNHQZCDQJBOV-ZPFDUUQYSA-N Leu-Ile-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O USLNHQZCDQJBOV-ZPFDUUQYSA-N 0.000 description 2
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 2
- KTOIECMYZZGVSI-BZSNNMDCSA-N Leu-Phe-His Chemical compound C([C@H](NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=CC=C1 KTOIECMYZZGVSI-BZSNNMDCSA-N 0.000 description 2
- PTRKPHUGYULXPU-KKUMJFAQSA-N Leu-Phe-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O PTRKPHUGYULXPU-KKUMJFAQSA-N 0.000 description 2
- IWMJFLJQHIDZQW-KKUMJFAQSA-N Leu-Ser-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IWMJFLJQHIDZQW-KKUMJFAQSA-N 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- VHNOAIFVYUQOOY-XUXIUFHCSA-N Lys-Arg-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VHNOAIFVYUQOOY-XUXIUFHCSA-N 0.000 description 2
- AAORVPFVUIHEAB-YUMQZZPRSA-N Lys-Asp-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O AAORVPFVUIHEAB-YUMQZZPRSA-N 0.000 description 2
- QQUJSUFWEDZQQY-AVGNSLFASA-N Lys-Gln-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCCN QQUJSUFWEDZQQY-AVGNSLFASA-N 0.000 description 2
- DUTMKEAPLLUGNO-JYJNAYRXSA-N Lys-Glu-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DUTMKEAPLLUGNO-JYJNAYRXSA-N 0.000 description 2
- QOJDBRUCOXQSSK-AJNGGQMLSA-N Lys-Ile-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(O)=O QOJDBRUCOXQSSK-AJNGGQMLSA-N 0.000 description 2
- WVJNGSFKBKOKRV-AJNGGQMLSA-N Lys-Leu-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVJNGSFKBKOKRV-AJNGGQMLSA-N 0.000 description 2
- XOQMURBBIXRRCR-SRVKXCTJSA-N Lys-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN XOQMURBBIXRRCR-SRVKXCTJSA-N 0.000 description 2
- HYSVGEAWTGPMOA-IHRRRGAJSA-N Lys-Pro-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O HYSVGEAWTGPMOA-IHRRRGAJSA-N 0.000 description 2
- FYRUJIJAUPHUNB-IUCAKERBSA-N Met-Gly-Arg Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N FYRUJIJAUPHUNB-IUCAKERBSA-N 0.000 description 2
- FZDOBWIKRQORAC-ULQDDVLXSA-N Met-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCSC)N FZDOBWIKRQORAC-ULQDDVLXSA-N 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 2
- 108010087066 N2-tryptophyllysine Proteins 0.000 description 2
- MPGJIHFJCXTVEX-KKUMJFAQSA-N Phe-Arg-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O MPGJIHFJCXTVEX-KKUMJFAQSA-N 0.000 description 2
- IEOHQGFKHXUALJ-JYJNAYRXSA-N Phe-Met-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IEOHQGFKHXUALJ-JYJNAYRXSA-N 0.000 description 2
- ZSKJPKFTPQCPIH-RCWTZXSCSA-N Pro-Arg-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZSKJPKFTPQCPIH-RCWTZXSCSA-N 0.000 description 2
- FKYKZHOKDOPHSA-DCAQKATOSA-N Pro-Leu-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FKYKZHOKDOPHSA-DCAQKATOSA-N 0.000 description 2
- GFHOSBYCLACKEK-GUBZILKMSA-N Pro-Pro-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O GFHOSBYCLACKEK-GUBZILKMSA-N 0.000 description 2
- KBUAPZAZPWNYSW-SRVKXCTJSA-N Pro-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KBUAPZAZPWNYSW-SRVKXCTJSA-N 0.000 description 2
- JDJMFMVVJHLWDP-UNQGMJICSA-N Pro-Thr-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JDJMFMVVJHLWDP-UNQGMJICSA-N 0.000 description 2
- FIXILCYTSAUERA-FXQIFTODSA-N Ser-Ala-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FIXILCYTSAUERA-FXQIFTODSA-N 0.000 description 2
- KNZQGAUEYZJUSQ-ZLUOBGJFSA-N Ser-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N KNZQGAUEYZJUSQ-ZLUOBGJFSA-N 0.000 description 2
- VDVYTKZBMFADQH-AVGNSLFASA-N Ser-Gln-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 VDVYTKZBMFADQH-AVGNSLFASA-N 0.000 description 2
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 2
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 2
- LRZLZIUXQBIWTB-KATARQTJSA-N Ser-Lys-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRZLZIUXQBIWTB-KATARQTJSA-N 0.000 description 2
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- MQCPGOZXFSYJPS-KZVJFYERSA-N Thr-Ala-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MQCPGOZXFSYJPS-KZVJFYERSA-N 0.000 description 2
- BSNZTJXVDOINSR-JXUBOQSCSA-N Thr-Ala-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BSNZTJXVDOINSR-JXUBOQSCSA-N 0.000 description 2
- VYEHBMMAJFVTOI-JHEQGTHGSA-N Thr-Gly-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O VYEHBMMAJFVTOI-JHEQGTHGSA-N 0.000 description 2
- HOVLHEKTGVIKAP-WDCWCFNPSA-N Thr-Leu-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O HOVLHEKTGVIKAP-WDCWCFNPSA-N 0.000 description 2
- UJQVSMNQMQHVRY-KZVJFYERSA-N Thr-Met-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O UJQVSMNQMQHVRY-KZVJFYERSA-N 0.000 description 2
- XGFYGMKZKFRGAI-RCWTZXSCSA-N Thr-Val-Arg Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N XGFYGMKZKFRGAI-RCWTZXSCSA-N 0.000 description 2
- MICSYKFECRFCTJ-IHRRRGAJSA-N Tyr-Arg-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O MICSYKFECRFCTJ-IHRRRGAJSA-N 0.000 description 2
- PJWCWGXAVIVXQC-STECZYCISA-N Tyr-Ile-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PJWCWGXAVIVXQC-STECZYCISA-N 0.000 description 2
- OLYXUGBVBGSZDN-ACRUOGEOSA-N Tyr-Leu-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 OLYXUGBVBGSZDN-ACRUOGEOSA-N 0.000 description 2
- OGPKMBOPMDTEDM-IHRRRGAJSA-N Tyr-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N OGPKMBOPMDTEDM-IHRRRGAJSA-N 0.000 description 2
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 2
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 2
- VLDMQVZZWDOKQF-AUTRQRHGSA-N Val-Glu-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N VLDMQVZZWDOKQF-AUTRQRHGSA-N 0.000 description 2
- AJNUKMZFHXUBMK-GUBZILKMSA-N Val-Ser-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N AJNUKMZFHXUBMK-GUBZILKMSA-N 0.000 description 2
- YQYFYUSYEDNLSD-YEPSODPASA-N Val-Thr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O YQYFYUSYEDNLSD-YEPSODPASA-N 0.000 description 2
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 2
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 2
- 108010005233 alanylglutamic acid Proteins 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 108010007483 arginyl-leucyl-tyrosyl-glutamic acid Proteins 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 108010092854 aspartyllysine Proteins 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- 229940097572 chloromycetin Drugs 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 108010069495 cysteinyltyrosine Proteins 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 108010087823 glycyltyrosine Proteins 0.000 description 2
- 108010025306 histidylleucine Proteins 0.000 description 2
- 108010092114 histidylphenylalanine Proteins 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229910001410 inorganic ion Inorganic materials 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 2
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 2
- 108010075702 lysyl-valyl-aspartyl-leucine Proteins 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000012533 medium component Substances 0.000 description 2
- 238000012269 metabolic engineering Methods 0.000 description 2
- 108010016686 methionyl-alanyl-serine Proteins 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000004108 pentose phosphate pathway Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 108010004914 prolylarginine Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 108010048818 seryl-histidine Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108010031491 threonyl-lysyl-glutamic acid Proteins 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 108700004896 tripeptide FEG Proteins 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 108010080629 tryptophan-leucine Proteins 0.000 description 2
- 108010078580 tyrosylleucine Proteins 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- WTFXTQVDAKGDEY-UHFFFAOYSA-N (-)-chorismic acid Natural products OC1C=CC(C(O)=O)=CC1OC(=C)C(O)=O WTFXTQVDAKGDEY-UHFFFAOYSA-N 0.000 description 1
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
- OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 description 1
- UWOCFOFVIBZJGH-YFKPBYRVSA-N (S)-2,3-dihydrodipicolinic acid Chemical compound OC(=O)[C@@H]1CC=CC(C(O)=O)=N1 UWOCFOFVIBZJGH-YFKPBYRVSA-N 0.000 description 1
- UFUQINYQINJWIL-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridine-2,3-dicarboxylic acid Chemical compound OC(=O)C1CC=CNC1C(O)=O UFUQINYQINJWIL-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- LXCUAFVVTHZALS-UHFFFAOYSA-N 3-(3-methoxyphenyl)piperidine Chemical compound COC1=CC=CC(C2CNCCC2)=C1 LXCUAFVVTHZALS-UHFFFAOYSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- 108010088237 ATCGAT-specific type II deoxyribonucleases Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101100301559 Bacillus anthracis repS gene Proteins 0.000 description 1
- WTFXTQVDAKGDEY-HTQZYQBOSA-N Chorismic acid Natural products O[C@@H]1C=CC(C(O)=O)=C[C@H]1OC(=C)C(O)=O WTFXTQVDAKGDEY-HTQZYQBOSA-N 0.000 description 1
- 101100247969 Clostridium saccharobutylicum regA gene Proteins 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- FNZLKVNUWIIPSJ-UHNVWZDZSA-N D-ribulose 5-phosphate Chemical compound OCC(=O)[C@H](O)[C@H](O)COP(O)(O)=O FNZLKVNUWIIPSJ-UHNVWZDZSA-N 0.000 description 1
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 108010005054 Deoxyribonuclease BamHI Proteins 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 101100412434 Escherichia coli (strain K12) repB gene Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- YPZRHBJKEMOYQH-UYBVJOGSSA-N FADH2 Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010089133 GGTACC-specific type II deoxyribonucleases Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 206010020674 Hypermetabolism Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- YEJCDKJIEMIWRQ-UHFFFAOYSA-N Linopirdine Chemical compound O=C1N(C=2C=CC=CC=2)C2=CC=CC=C2C1(CC=1C=CN=CC=1)CC1=CC=NC=C1 YEJCDKJIEMIWRQ-UHFFFAOYSA-N 0.000 description 1
- -1 MTHF tetrahydrofolic acid methyl esters Chemical class 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 102100032457 NAD-dependent malic enzyme, mitochondrial Human genes 0.000 description 1
- 102100023175 NADP-dependent malic enzyme Human genes 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- FNZLKVNUWIIPSJ-UHFFFAOYSA-N Rbl5P Natural products OCC(=O)C(O)C(O)COP(O)(O)=O FNZLKVNUWIIPSJ-UHFFFAOYSA-N 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101100114425 Streptococcus agalactiae copG gene Proteins 0.000 description 1
- 102100033055 Transketolase Human genes 0.000 description 1
- 108010043652 Transketolase Proteins 0.000 description 1
- RNDWCRUOGGQDKN-UBHSHLNASA-N Trp-Ser-Asp Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O RNDWCRUOGGQDKN-UBHSHLNASA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- UXRDAJMOOGEIAQ-CKOZHMEPSA-N [(8r,9s,10r,13s,14s,17r)-17-acetyl-10,13-dimethyl-16-methylidene-3-oxo-1,2,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 UXRDAJMOOGEIAQ-CKOZHMEPSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- PPQRONHOSHZGFQ-LMVFSUKVSA-L aldehydo-D-ribose 5-phosphate(2-) Chemical compound [O-]P(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-L 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 101150049515 bla gene Proteins 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 101150054175 cro gene Proteins 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 101150011371 dapA gene Proteins 0.000 description 1
- 101150073654 dapB gene Proteins 0.000 description 1
- 101150009649 dapC gene Proteins 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 108010038291 endodeoxyribonuclease PvuI Proteins 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 108010055246 excisionase Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011900 installation process Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000012204 lemonade/lime carbonate Nutrition 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229910001437 manganese ion Inorganic materials 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- FPWMCUPFBRFMLH-HDKIZWTHSA-N prephenic acid Chemical compound O[C@H]1C=C[C@](CC(=O)C(O)=O)(C(O)=O)C=C1 FPWMCUPFBRFMLH-HDKIZWTHSA-N 0.000 description 1
- FPWMCUPFBRFMLH-UHFFFAOYSA-N prephenic acid Natural products OC1C=CC(CC(=O)C(O)=O)(C(O)=O)C=C1 FPWMCUPFBRFMLH-UHFFFAOYSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 101150044854 repA gene Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- JDTUMPKOJBQPKX-GBNDHIKLSA-N sedoheptulose 7-phosphate Chemical compound OCC(=O)[C@@H](O)[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O JDTUMPKOJBQPKX-GBNDHIKLSA-N 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 101150112970 up gene Proteins 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
通过以下步骤测定影响细胞进行物质生产的代谢流量:1)基于底物到目标产物的生化反应式建立化学计量矩阵;2)从所有代谢流量中选择与化学计量矩阵自由度相同数量的独立代谢流量作为自由流量;3)建立足够数量的自由流量的随机组合进行统计分析,并基于化学计量矩阵从各建立的组合计算代谢流量分布;4)通过多元统计分析,从计算出的代谢流量分布获得回归方程,其包括最小数量的显示与物质生产相关的自由流量;5)基于所得回归方程中的系数确定至少一种影响物质生产的代谢流量。
Description
技术领域
本发明涉及影响物质生产的代谢流量的测定方法、使用该测定方法构建菌株的方法、执行该测定方法的程序和存储程序的记录介质。
背景技术
代谢流量分析,又被称为流量平衡分析,是通过建立细胞内生化反应的化学计量模型和线性优化,预测细胞内代谢流量分布的技术。这项技术已被用于研究微生物生化反应系统的能力,或预测不同外界条件下胞内代谢流量的分布(非专利文件1、2和3)。构建大肠杆菌(Escherichia coli)的化学计量模型也有报道(非专利文件4和5)。也已知在谷氨酸棒状杆菌(Corynebacterium glutamicum)生产赖氨酸的代谢工程中使用这种化学计量模型的实例(非专利文件6)。此外,报道了大量的代谢流量分析的理论性和实验性方法,以及它们的应用(非专利文件7、8,专利文件1、2和3)。专利文件1公开了基于化学计量模型预测生长必需基因的方法。专利文件2公开了遗传或进化改变细胞以赋予细胞最优功能的技术。此外,专利文件3公开了将定性动力学信息的限制、定性控制信息的限制和基于不同条件下DNA微点阵实验数据的限制应用于化学计量模型的方法。尽管所有这些方法都是预测更多所需的胞内代谢流量分布的方法,但是没有任何一种方法公开理论上预测作为目标的流量,以直接提高细胞的物质生产。
<非专利文件1>
Varma,A.和Palsson,.B.O.Appl.Environ.Microbiol.60:3724-3731,1994
<非专利文件2>
Schilling,C.H等,Biotechnol.Prog.,15:288-295,1999
<非专利文件3>
Schilling,C.H.等,Biotechnol.Prog.,15:296-303,1999
<非专利文件4>
Pramanik,J.和Keasling,J.D.,Biotechnol.Bioeng.,56:398-421,1997
<非专利文件5>
Ibarra,R.U.等,Nature,420:186-189,2002
<非专利文件6>
Vallino,J.J.和Stephanopoulos,G.,Biotechnol.Bioeng.,41:633-646,
1993
<非专利文件7>
Wiechert,W.,Journal of Biotechnology,94:37-63,2002
<非专利文件8>
Wiechert,W.,Metabolic Engineering,3:195-205,2001
<专利文件1>
国际申请号WO00/46405
<专利文件2>
国际申请号WO02/061115
<专利文件3>
国际申请号WO02/055995
发明公开
本发明提供了一种方法,通过使用胞内代谢流量分析预测修饰细胞的有效方法,以提高目标产物或生物量的产率,和使用细胞如微生物细胞生产物质(如氨基酸、有机酸和核酸)中产物的生产力。更具体而言,本发明提供了影响物质生产的代谢流量的测定方法、使用该测定方法生产细菌菌株的方法、执行该测定方法的程序和储存程序的记录介质。
考虑到上述目的,本发明的发明者们进行了艰苦的研究,最终他们发现可如下测定影响物质生产的代谢流量:基于底物到目标产物(待生产物质)的生化反应式计算化学计量矩阵的自由度,选择与该自由度相同数量的自由流量;基于该化学计量矩阵,从足够进行统计分析的数量的各自由流量随机组合计算代谢流量分布;基于统计分析,从计算出的代谢流量分布得到回归方程,其包含最小数量的与物质生产相关的自由流量。基于上述发现实现了本发明,至少包括如下:
(1)一种用于测定至少一种影响使用细胞生产物质的代谢流量的方法,该方法包括如下步骤:
1)基于底物到目标产物的生化反应式建立化学计量矩阵,
2)从所有代谢流量中选择与化学计量矩阵自由度相同数量的独立代谢流量作为自由流量,
3)建立足够数量的自由流量的随机组合进行统计分析,并基于化学计量矩阵从各建立的组合计算代谢流量分布,
4)通过多元统计分析,从计算出的代谢流量分布获得回归方程,其包括最小数量的显示与物质生产相关的自由流量,
5)基于所得回归方程的系数确定至少一种影响物质生产的代谢流量。
(2)(1)的方法,其中该统计分析为多元线性回归分析。
(3)(1)或(2)的方法,其中细胞为有能力产生氨基酸、核酸或有机酸的微生物细胞。
(4)一种用于构建具有物质生产能力的菌株的方法,其包括修饰菌株,以至在通过(1)-(3)任一项定义的方法测定的影响物质生产的代谢流量中,或在任何属于相同独立代谢流量组(包括该代谢流量)的代谢流量中,当代谢流量显示与物质生产正相关时增加其相应活性,或当代谢流量显示与物质生产负相关时降低其相应活性,或两者兼有。
(5)一种生产物质的方法,包括将通过(4)中定义的方法构建的菌株培养于培养基中,以在培养基或细菌细胞中生产和累积物质,并从培养基或细胞中收集物质,其中物质为氨基酸、核酸或有机酸。
(6)一种用于测定至少一种影响使用细胞生产物质的代谢流量的程序,该程序允许计算机执行代谢流量测定方法,包含以下程序:
1)基于底物到目标产物的生化反应式建立化学计量矩阵,
2)从所有代谢流量中选择与化学计量矩阵自由度相同数量的独立代谢流量作为自由流量,
3)建立足够数量的自由流量的随机组合进行统计分析,并基于化学计量矩阵从各建立的组合计算代谢流量分布,
4)通过多元统计分析,从计算出的代谢流量分布获得回归方程,其包括最小数量的显示与物质生产相关的自由流量,
5)基于回归方程中获得的系数确定至少一种影响物质生产的代谢流量。
(7)一种计算机可读的记录介质,其记录了(6)中定义的程序。
附图简述
图1是用5000个随机流量分布的数据组将赖氨酸的生产显示为不同自由流量值的函数的图形。赖氨酸产率显示为(a)异柠檬酸裂合酶流量、(b)苹果酸酶流量和(c)磷酸烯醇式丙酮酸羧化酶流量。
图2是将赖氨酸的生产显示为5000个随机流量分布的数据组在方程2中的值的函数图形。输入值为基于10mmol/小时葡萄糖流量,以mmol/小时为单位的流量值。
图3显示代谢流量测定程序的流程图。
图4显示pMW118-attL-Tc-attR和pMW118-attL-Cm-attR的结构。
图5显示pMW-intxis-ts的结构。
实施本发明的最佳方式
下文将详细解释说明本发明。
<1>本发明的测定方法
本发明的测定方法是测定影响使用细胞进行物质生产的代谢流量的方法。
用于本发明的代谢流量被表述为代谢反应速率(流量),其来源于胞内生化反应的化学计量模型和代谢产物之间的质量作用定律;同时,本文使用的代谢流量分布由所有的代谢流量组成,其中每一个代谢流量被指定到各生化反应。
用于本发明的细胞并没有特别限制,只要它用于物质生产。其实例包括各种培养的细胞、真菌、酵母、各种细菌等。优选为有能力产出有用化合物如氨基酸、核酸或有机酸的微生物细胞。作为有能力产生氨基酸、核酸或有机酸的微生物,优选使用大肠杆菌(Escherichia coli)、芽孢杆菌(Bacillus bacteria)、棒状杆菌(coryneformbacteria)等。更优选使用具有氨基酸生产能力和/或有机酸生产能力的微生物。这种微生物有能力产生有用的化合物,例如,显示于EP-A1016710的大肠杆菌,显示于JP-A 2003-259861的芽孢杆菌,显示于WO 00/18935的棒状杆菌。基于可通过本发明获得的影响物质生产的代谢流量的信息,修饰微生物,以提高它的物质生产能力。
在本发明测定方法的第一步中,基于底物到目标物质产物的生化反应式建立化学计量矩阵。
生化反应指在细胞内胞内代谢物通过酶促反应转变的过程,并根据生物类型被编到不同的数据库。例如Kyoto Encyclopedia of Genesand Genomes(KEGG,www.genome.ad.jp/kegg/)可供查询参考。
底物通常是被细胞作为碳源使用的物质,其实例包括葡萄糖、蔗糖、果糖等。
物质产物不仅包括单一种类的代谢产物,而且包括代谢产物的聚集体,例如生物量(细胞体)。物质生产通常被评价为物质的生产速率。具体而言,当目标物质是生物量时,它被评价为生物量产率。生物量产率代表了从底物如葡萄糖转化为细胞组分如蛋白、碳水化合物、核酸或脂类的效率。
化学计量矩阵是通常用于代谢流量分析的矩阵,可以通过用于代谢流量分析的典型方法,列举底物到目标物质产物的生化反应式来建立。这种方法是熟知的,假定胞内代谢中间体是准稳态(Savinell,J.M.和Palsson,B.O.J.,Theor.Biol.,154:421-454,1992;Vallino,J.J.和Stephanopoulos,G.,Biotechnol.Bioeng.,41:633-646,1993)。当列出反应式时,通过假定一系列没有分支的反应为一个反应,或假定在反应之前和之后由该反应以高代谢速率转化的多个代谢产物为一个代谢产物等等,可简化反应途径。当物质生产是生物量时,可以通过列出生成细胞成分的生化反应来描述化学计量矩阵。
在本发明测定方法的第二步中,从所有代谢流量中选择与上述化学计量矩阵自由度相同数量的独立代谢流量作为自由流量。
独立流量是一组流量,其在以化学计量方程式表示的代谢网络系统中应指定为唯一定义的流量。
设置自由流量的方法并没有特别限制,只要可选择与待分析的系统的自由度相同数量的独立代谢流量。尽管可证实任意选择的流量的独立性,也可以使用由Reder提出的SIMS矩阵(稳定状态体内代谢化学计量矩阵)(Reder,C.J.,Theor.Biol.,135:175-201,1988)。在这种方法中,基于上述生化反应式确定独立的代谢流量组,从中选择与上述化学计量矩阵自由度相同数量的特定代谢流量组,并从每个确定的代谢流量组中选出一个代谢流量作为自由流量。在流量组中测定特异组以保证组中的任何流量都可变化而不影响其它组中的流量。因此,有可能从各组中选择一个流量作为独立的自由流量。当从一组流量中选择一个自由流量时,优选选择接近分支点的流量。
在本发明测定方法的第三步中,建立数量足以进行统计分析的自由流量随机组合,并基于上述化学计量矩阵从建立的各组合中计算代谢流量分布。
通过给予先前步骤中选择的自由流量以随机值,可建立自由流量的随机组合,以建立不同流量分布组合的数据组。给予自由流量随机值的方法并没有特别限定,只要选择的方法在特定的界限内产生自由流量的组合。设定所述特定的界限是为了在稍后计算中得到生物学可行的值。假如自由流量的数值与指定的化学计量矩阵的自由度相同,则可以解出唯一的一个代谢流量分布。通常使用逆矩阵对矩阵进行求解,并且优选将所有流量都标准化为,例如,一定量的底物。当底物是葡萄糖时,所有的流量值可用如每摄入10mmol葡萄糖的值来表示。如上描述的从随机自由流量值得到的代谢流量分布的解必须具有生物学意义。也就是说,所有不可逆反应的流量必须大于等于0,形成生物量的流量必须大于等于0。为得到更多所需自由流量的组合,也可增加基于使用细胞生产物质的理论和/或经验性知识的条件。待建立的组合的数量,也就是待计算的具有生物学意义的流量分布数量,并无特别限定,只要它足够进行统计分析。一个自由流量通常使用三个或五个值。因此,当有n个自由流量时,组合的数目大约是一个自由流量值的数量的n次幂。例如,当一个自由流量使用3个值时,就有3至3的n次幂(3n)个组合。也就是,对七个自由流量(n=7)可使用约2200个组合。或者,在有生物学意义的流量分布的数据组中,各自由流量值的数量可以根据选择的自由流量或另外的条件变化,对于n个自由流量,可使用组合的数量为总计约3至3的n次幂(3n)到约5至5的n次幂(5n)。为获得如此数量的有生物学意义的流量分布的解,典型从使用一个自由流量6-10个值的随机自由流量组合开始,也就是6至6的n次幂(6n)到10至10的n次幂(10n)个自由流量的组合。
在本发明的测定方法的第四步中,通过多元统计分析,从代谢流量分布(代谢流量分布的数据组)获得回归方程,其包括最小数量的显示与物质生产相关的自由流量。
通过从先前步骤中获得的自由流量的随机组合计算流量分布数据组,对数据组进行多元统计分析,可以获得回归方程,其包括最小量的显示与物质生产相关的自由流量。可使用任何技术进行多元统计分析(包括多元非线性回归分析和多元线性回归分析),只要选择的技术可检验自由流量组合与物质生产之间的相关性。但是,多元线性回归分析是有用的。这种方法描述于,例如,Kachigan,S.K.,第四章,多元统计分析中的回归分析(Regression Analysis in MultivariateStatistical Analysis),第二版,Radius Press,New York,pp.160-193。
表述“显示物质生产相关”意指可决系数显著大,“显著大”通常意味着可决系数R2为0.8或更高,优选为0.9或更高。
包括最小数量的显示与物质生产相关的自由流量(项(term))的回归方程,可通过连续变化项数来获得。这种方程显示最大可决系数(包括各项数),并能选择包括最小项数、显示显著大可决系数的回归方程。或者,可获得带有某一项以外所有项的回归方程,以检验除去该项所引起的可决系数的下降程度;重复这个过程,将显示引起可决系数小程度下降以外的项作为全部项;当不能再得到与物质生产相关的回归方程时,可选择之前得出的回归方程。
在本发明测定方法的第五步中,根据获得的回归方程中的系数确定影响物质生产的代谢流量。
自由流量有助于使用细胞如微生物进行物质生产,尤其是在物质生产中重要的生物量产率或产物物质产率,这种贡献可通过利用先前步骤获得的回归方程确定。也就是,在回归方程中出现的自由流量可确定为影响物质生产的自由流量。此外,因为回归方程中的系数代表贡献的大小,具有相当大的可决系数的自由流量(当标准化流量时,相对系数绝对值大的自由流量)可被确定为极大影响物质生产的代谢流量。
本发明的测定方法可提供对改进菌株重要的信息,即哪些自由流量极大影响目标物质的生产,无论自由流量对目标物质的生产产生正面或负面影响。还可预测出需要改变以有利影响目标产物的产率和生产力的流量。
<2>本发明的构建方法
本发明的构建方法为用于构建具有物质生产能力的菌株的方法。该方法包括修饰细菌菌株,以至在通过本发明测定方法确定的影响物质生产的代谢流量中,或者任何属于包括该代谢流量的相同独立代谢流量组的代谢流量中,当代谢流量显示与物质生产正相关时相应的活性增强,和/或当代谢流量显示与物质生产负相关时相应的活性减弱。
除了由本发明的测定方法确定的代谢流量,也可以改变引起任何代谢流量的活性,该代谢流量属于包括该代谢流量的相同独立代谢流量组,因为认为包括在相同代谢流量组中的代谢流量具有相同的效应。然而,预期实际代谢工程技术的难易和酶活性变化的效应强度都根据引起流量的酶而变化。假如考虑改进生产细菌的劳动和效果,可预期接近分支点的流量将是有效的。例如,在戊糖磷酸途径中,预期选择葡糖-6-磷酸脱氢酶与选择转羟乙醛酶一样有效。
已知各种方法用于改变引起特定流量的活性。对于增强酶活性的方法,已知通过使用染色体外DNA如质粒增加编码酶的基因的拷贝数、或增加染色体拷贝数、在编码酶的基因的启动子中引入突变以增强活性、使用更强的启动子取代。对于减弱酶活性的方法,已知破坏编码酶的基因或者在该基因中引入突变以减弱活性、在编码酶的基因的启动子中引入突变以减弱活性、使用更弱启动子取代该启动子。通过这些方法,可以改变引起特定流量的活性,以提高目标产物的产率和生产力。例如,如随后实施例中所描述的,可预期在使用大肠杆菌的赖氨酸生产中,通过增强磷酸烯醇式丙酮酸羧化酶的活性,可构建出赖氨酸生产能力提高的细菌菌株,国际公开WO01/53459公开了通过增强磷酸烯醇式丙酮酸羧化酶活性提高赖氨酸产生的实例。因此,已证实基于本发明测定方法的本发明构建方法极其有用。
<3>本发明的生产方法
本发明的方法为生产氨基酸、核酸或有机酸的方法,其包括以下步骤:在培养基中培养具有氨基酸、核酸或有机酸生产能力的细菌,导致在培养基或细菌细胞中累积氨基酸、核酸或有机酸,并从培养基或细胞中收集氨基酸、核酸或有机酸。本文使用的术语“核酸”是指核苷或核苷酸。
用于本发明的培养基可以是典型用于使用微生物发酵生产氨基酸、核酸或有机酸的培养基。假如需要,也可使用包含碳源、氮源、无机离子和其它有机成分的普通培养基。对于碳源,可使用各种糖类如葡萄糖、蔗糖、乳糖、半乳糖、果糖和淀粉水解物,各种醇如甘油和山梨醇,各种有机酸如延胡索酸、柠檬酸和琥珀酸。对于氮源,可使用各种无机铵盐如硫酸铵、氯化铵和磷酸铵,有机氮如大豆水解物,氨气和氨水等。对于微量有机营养素,希望添加需要的物质如维生素B1、高丝氨酸或酵母提取物等。此外,也可添加微量的磷酸钾、硫酸镁、铁离子、锰离子。用于培养的培养基可以是合成培养基或天的培养基,只要该培养基包含碳源、氮源和无机离子,假如需要,包含微量有机营养素。
优选在需氧条件下进行培养,在24-37℃温度、pH5-9下培养1-7天。可使用无机酸或有机酸或碱性物质(例如氨气)等调节培养物的pH。可通过常规的方法如离子交换树脂方法、沉淀和其它已知的方法或其组合,从培养基中收集氨基酸、核酸或有机酸。当氨基酸、核酸或有机酸在细胞中累积时,通过超声波等破碎细胞,并通过离心去除细胞碎片获得上清,从中可通过离子交换树脂方法等等收集氨基酸、核酸或有机酸。
<4>本发明的程序
本发明也提供了执行本发明测定方法的程序。本发明的程序为用于测定至少一个影响使用细胞进行物质生产的代谢流量的程序,该程序允许计算机执行包括以下步骤的代谢流量测定方法:
1)基于底物到所需目标产物的生化反应式建立化学计量矩阵,
2)从所有代谢流量中选择与化学计量矩阵自由度相同数目的独立代谢流量作为自由流量,
3)建立足够数量的自由流量的随机组合用于统计分析,并基于化学计量矩阵从各建立的组合计算代谢流量分布,
4)通过多元统计分析,从计算出的代谢流量分布获得回归方程,其包括最小数量的与物质生产相关的自由流量,
5)基于所得到的回归方程中的系数确定至少一种影响物质生产的代谢流量。
此外,本发明的另一方面涉及计算机可读的记录介质,其特征为它记录了上述程序。
本发明程序的流程图显示在图3中。各过程都是执行本发明测定方法中步骤1)-5)的各步的过程。依据常用编程方法可建立允许计算机执行这些过程的程序。
此外,本发明的程序也可被存储在计算机可读的记录介质中。本文使用的术语“记录介质”包括任何“可移动物理介质”如软盘(注册商标名)、磁光盘、ROM、EPROM、EEPROM、CD-ROM、MO和DVD,任何“固定物理介质”如设置在各种计算机系统中的ROM、RAM和HD,以及用以临时存储程序的“通信介质”如通信电路和载波,用于经LAN、WAN和Internet代表的网络传输程序。
此外,该“程序”是一种处理数据的程序,其以任意语言或操作符号编写,它的格式如源代码或二进制码没有限制。该“程序”没有必要限定于单个程序,包括包含两个或更多模块或库的分布式结构中描述的程序,或通过与操作系统(OS)代表的单个程序联合来实现它的功能。众所周知的配置和程序可用作特定的配置,用于读取存储于记录介质中的程序、读取过程、读取之后的安装过程等等,各装置显示于实施例中。
实施例
通过参考实施例进一步详细描述本发明。
实施例1
关于L-赖氨酸的代谢流量的测定
(1)建立化学计量矩阵
通过假定胞内代谢中间体的准稳态,构建用于计算代谢流量的化学计量方程(Savinell,J.M.和Palsson,B.O.J.,Theor.Biol.,154:421-454,1992;Vallino,J.J.和Stephanopoulos,G.,Biotechnol.Bioeng.,41:633-646,1993)。这个模型包括的反应式显示于表2中。表1列出了本发明所用的略写的说明。合并一些无分支的反应以简化公式。因为磷酸戊糖途径很复杂,将其用两个公式表示。生物量的成分比例使用报道的数据(Neidhardt,F.C.et al.,Physiology of the Bacterial Cell.,Sinauer Associates,Massachusetts,1990),生物量通过使用反应式[68]表示。这个模型中化学计量矩阵的自由度为7。
表1
3PG 3-磷酸-D-甘油酸
AcCoA 乙酰辅酶A
AcOH 乙酸
aVIVA A-酮-异戊酸
aKG 2-酮戊二酸
Ala 丙氨酸
ALC 乙酰羟酸
Arg 精氨酸
ASA 天冬氨酸半醛
Asn 天冬酰胺
Asp 天冬氨酸
CHR 分支酸
Cit 柠檬酸
CO2 二氧化碳
CoA 辅酶A
Cys 半胱氨酸
DDP 二氢吡啶二羧酸
E4P 赤藓糖-4-磷酸
F6P 果糖-6-磷酸
FBP 二磷酸果糖
Form 甲酸
Fum 延胡索酸
G6P 葡萄糖-6-磷酸
GAP 磷酸甘油醛
Glc 葡萄糖
Gln 谷氨酰胺
Glu 谷氨酸
Gly 甘氨酸
Glyox 乙醛酸
His 组氨酸
Hse 高丝氨酸
Ile 异亮氨酸
Ind 吲哚甘油磷酸
Isoci 异柠檬酸
Leu 亮氨酸
Lys 赖氨酸
Lysext 赖氨酸产物(胞外)
Mal 苹果酸
Met 甲硫氨酸
mDAP 内消旋二氨基庚二酸
mTHF 四氢叶酸甲酯
NH3 氨
OAA 草酰乙酸
PEP 磷酸烯醇式丙酮酸
Phe 苯丙氨酸
PPA 预苯酸
Pro 脯氨酸
PRPP 磷酸核糖焦磷酸
Pyr 丙酮酸
R5P 核糖-5-磷酸
Ribu5P 5-磷酸核酮糖
SDAP N-琥珀酰-L-2,6-二氨基庚二酸
SKA 莽草酸
Sed7P D-景天庚酮糖-7-磷酸
Ser 丝氨酸
Suc 琥珀酸
SucCoA 琥珀酰辅酶A
THDP 四氢吡啶二羧酸
THF 四氢叶酸
Thr 苏氨酸
Trp 色氨酸
Tyr 酪氨酸
Val 缬氨酸
X5P 5-磷酸木酮糖
表2使用的反应式列表。可逆反应标记有r。
[1] Glc+PEP-->G6P+Pyr
[2] G6P+2NADP-->Ribu5P+2NADPH+CO2
[3]r Ribu5P-->R5P
[4]r Ribu5P-->X5P
[5]r X5P+R5P-->Sed7P+GAP
[6]r Sed7P+GAP-->E4P+F6P
[7]r X5P+E4P-->F6P+GAP
[8]r G6P-->F6P
[9]r F6P+ATP-->FBP+ADP
[10]r FBP-->2GAP
[11]r GAP+NAD+ADP-->3PG+NADH+ATP
[12]r 3PG-->PEP
[13] PEP+ADP-->Pyr+ATP
[14] Pyr+NAD+CoA-->AcCoA+NADH+CO2
[15] PEP+CO2-->OAA
[16] AcCoA+ADP-->AcOH+ATP+CoA
[17] AcCoA+OAA-->Cit+CoA
[18]r Cit-->Isocit
[19]r Isocit+NADP-->aKG+NADPH+CO2
[20] aKG+NADPH+NH3-->Glu+NADP
[21] aKG+NAD+CoA-->SucCoA+NADH+CO2
[22]r SucCoA+ADP-->Suc+ATP+CoA
[23]r Suc+FAD-->Fum+FADH
[24]r Fum-->Mal
[25]r Mal+NAD-->OAA+NADH
[26] OAA+Glu-->Asp+aKG
[27] Asp+ATP+NADPH-->ASA+ADP+NADP
[28] ASA+Pyr-->DDP
[29] DDP+NADPH-->THDP+NADP
[30] THDP+SucCoA+Glu-->SDAP+aKG+CoA
[31] SDAP-->mDAP+Suc
[32] mDAP-->Lys+CO2
[33]r Glu+ATP+NH3-->Gln+ADP
[34] Glu+2NADPH+ATP-->Pro+2NADP+ADP
[35] Glu+5ATP+NADPH+Gln+Asp+AcCoA+CO2-->Arg
+5ADP+NADP+aKG+Fum
[36] ASA+NADPH-->Hse+NADP
[37] Hse+SucCoA+Cys+mTHF-->Met+Suc+CoA+THF+
Pyr+NH3
[38] Hse+ATP-->Thr+ADP
[39] Thr+Glu+NADPH+Pyr-->Ile+aKG+NADP+NH3+
CO2
[40]r 3PG-->Ser
[41]r Ser+THF-->Gly+mTHF
[42]r PEP+E4P+NADPH-->SKA+NADP
[43] CHR-->PPA
[44] PPA+NAD+Glu-->Tyr+NADH+CO2+Akg
[45] PPA+Glu-->Phe+CO2+aKG
[46] CHR+R5P+2ATP+Gln-->Ind+Glu+Pyr+CO2+GAP
+2ADP
[47] 2Pyr-->ALC
[48] aIVA+Glu-->Val+aKG
[49] Val+Pyr-->ALA+aIVA
[50] aIVA+AcCoA+NAD+Glu-->Leu+NADH+CO2+aKG
+CoA
[51] PRPP+ATP+Gln+Glu+2NAD-->His+ADP+Glu+
aKG+2NADH
[52] Ser+AcCoA+H2S-->Cys+AcOH
[53] SKA+PEP+ATP-->CHR+ADP
[54] Ind+Ser-->Trp
[55] ALC+NADPH-->aIVA+NADP+CO2
[56]r NADH-->NADPH
[57] 2NADH+O2+2ADP-->2ATP+2NAD
[58] 2FADH+O2+ADP-->ATP+2FAD
[59]r Asp+2ATP+NH3-->Asn+2ADP
[60] Isocit-->Glyox+Succ
[61] AcCoA+Glyox-->Mal+CoA
[62] Mal+NAD-->Pyr+CO2+NADH
[63]r R5P+2ATP-->PRPP+2ADP
[64] mTHF+NADP-->NADPH+THF+Form
[65] NAD+Gly+THF-->mTHF+NADH+CO2+NH3
[66] ATP-->ADP
[67] Lys-->Lysext
[68]生物量合成(如下描述)
RNA(21.33%)
3.47PRPP+5.02Gln+-5.02Glu+3.08Gly+6.17Asp+32.41ATP
+-32.41ADP+6.17mTHF+-6.17THF+3.09NAD+-3.09NADH
+6.17NADP+-6.17NADPH+1.16CO2+-3.47Fum+-3.86NH3
DNA(3.23%)
3.37PRPP+4.88Gln+-4.88Glu+3Gly+6Asp+31.5ATP+-31.5
ADP+7.12mTHF+-7.12THF+3NAD+-3NADH+3.75NADP+-
3.75NADPH+1.12CO2+-3.37Fum+-3.75NH3
磷脂(9.47%)
20.8AcCoA+-20.8CoA+1.95GAP+0.65Ser+44.2ATP+-44.2
ADP+38.35NADH+-38.35NAD+-0.65CO2
肽聚糖(2.60%)
1.94F6P+1.94AcCoA+-1.94CoA+1.94Gln+-1.94Glu+2.91Ala
+0.97PEP+0.97Lys+6.97ATP+-6.97ADP+0.97NADPH+-0.97
NADP+-0.97CO2
脂多糖(3.54%)
0.91R5P+0.91F6P+0.91PEP+15.47AcCoA+-0.91AcOH+-0.91
Glu+0.91Gln+32.76ATP+12.74NADH
蛋白(57.23%)
0.77Gly+0.96Ala+0.67Val+0.85Leu+0.44Ile+0.44Ser+0.48
Thr+0.30Phe+0.26Tyr+0.01Trp+0.15Cys+0.22Met+0.54Lys
+0.46Arg+0.16His+0.46Asp+0.52Glu+0.46Asn+0.52Gln+
0.34Pro
糖原(2.60%)
F6P+ATP
(2)自由流量的选择和其随机组合的建立
依据Reder的方法(Reder,C.J.,Theor.Biol.,135:175-201,1988)测定特定的流量组。从各组中选择接近分支点的流量。表3显示了七个选择的自由流量。通过指定这7个流量可获得流量平衡的唯一解。
表3
获得随机流量分布的自由流量列表
反应编码 | 酶名称或反应途径名称 |
2 | 葡糖-6-磷酸脱氢酶 |
15 | PEP羧化酶 |
16 | 乙酸分泌 |
60 | 异柠檬酸裂合酶(乙醛酸循环) |
62 | 苹果酸酶 |
64 | 甲酸分泌 |
66 | ATP酶 |
从7个随机自由流量的约300,000个组合的值中,去除任何超过可逆反应极限的组合,以及显示的赖氨酸和生物量的值均没有超越阈水平的组合,阈水平定为每个最大值的20%。结果是,在有生物学意义的特定区域中创建了5000个代谢流量分布的数据组。基于10mmol葡萄糖摄取的值表示这些结果,建立了一个具有5000行(对应随机流量分布)和68列(对应反应流量)的矩阵。
(3)通过多元分析进行相关分析并确定影响物质生产的代谢流量
进行了压缩(condensed)矩阵的多元线性回归,其包括对应7个自由流量的列的Z分。使用MatLab统计工具包的逐步回归函数进行多元线性回归。使用这项技术,可用7个自由流量的线性函数衍生生物量或赖氨酸生产。对这7个流量进行鉴定导致系统状态的唯一定义。因此,假如所有的7项都用作参数,相关系数就变为1,表明完全符合。然而,用比方程中项数少的项数通常可得到相对有利的拟合。为了尝试项的各种组合,通过使用MatLab程序的逐步回归函数选择对包含项的各数量显示最佳拟合的方程。就生物量产率而言,仅用异柠檬酸裂合酶(ICL)、苹果酸酶(MEZ)、PEP羧化酶(PEPC)和ATP酶4项获得R2=0.980的拟合。当项的数目进一步减少时,R2值显著降低,不可能获得任何合理拟合。当标准化反应流量至每10mmol葡萄糖摄取值并用作输入时,精确的方程如下表示:
方程1)生物量产率=1.552-0.194(ICL)+0.184(MEZ)-0.194(PEPC)-0.011(ATP酶)。
赖氨酸产率可用包括相同4个参数的模型拟合,获得R2=0.997的结果。此外,甚至当除去ATP酶这项时,R2仅下降至0.856,仍然是较好的拟合。因此,赖氨酸模型使用以下3个参数。
方程2)赖氨酸产率=-1.694+1.176(ICL)-1.095(MEZ)+1.162(PEPC)
最后,用流向生物量和赖氨酸的C原子总数定义的总碳产率(C原子),通过如下方程,仅用ATP酶这项的拟合度达到R2=0.956。
方程3)C原子=34.3-0.314(ATP酶)
这些结果揭示生物量产率与苹果酸流量正相关,赖氨酸生产与PEP羧化酶流量和异柠檬酸裂合酶(乙醛酸循环)的流量正相关。图1和图2可显示该回归分析的有效性。当分开考虑异柠檬酸裂合酶流量和苹果酸酶流量时,没有发现与L-赖氨酸生产的相关性,如图1(a)和(b)所示。但是,如图2所示,当将这些流量作为回归方程2)的一部分考虑时,可观察到相关性,并且效果变得明显。因此,利用这项技术可揭示代谢流量间不可见的联系。提高显示正相关流量的活性和削弱显示负相关流量的活性可提高目标产物的产率。也就是说,从这个结果中可得到改进细菌菌株的方针,提高PEP羧化酶或异柠檬酸裂合酶活性或削弱显示负相关性的苹果酸酶活性对L-赖氨酸生产有效。事实上,在国际公开WO01/53459中公开了在利用大肠杆菌生产赖氨酸中通过提高PEP羧化酶活性,构建了显示产赖氨酸能力提高的细菌菌株的实例,并因此支持了本发明的有效性。
实施例2
关于L-苏氨酸的代谢流量的测定
用实施例1中同样的方法,选出关于L-苏氨酸的对包含项的各数量都拟合得最好的方程。就生物量产率而言,仅异柠檬酸裂合酶(ICl)、苹果酸酶(MEZ)、PEP羧化酶(PEPC)和ATP酶4项得到R2=0.986的拟合度。
方程4)生物量产率=1.260-0.101(ICL)+0.093(MEZ)-0.101(PEPC)-0.009(ATP酶)
苏氨酸产率可用包含同样3个参数的模型来拟合,获得R2=0.937的结果。
方程5)苏氨酸产率=-1.432+1.090(ICL)-1.080(MEZ)+1.087(PEPC)
这些结果揭示生物量产率与苹果酸酶流量正相关,苏氨酸生产与PEP羧化酶和异柠檬酸裂合酶(乙醛酸循环)的流量正相关。因此,关于苏氨酸生产,可得到改进细菌菌株的方针,提高PEP羧化酶或异柠檬酸裂合酶活性或削弱显示负相关性的苹果酸酶活性对L-苏氨酸生产有效。
实施例3
构建苹果酸酶缺陷的L-赖氨酸生产细菌
菌株WC196用作生产L-赖氨酸的大肠杆菌菌株,其具有AEC(S-(2-氨乙基)半胱氨酸)抗性(国际公开号WO 96/17930)。
来源于大肠杆菌的苹果酸酶包括以NAD为辅酶的酶(EC 1.1.1.38)和以NADP为辅酶的酶(EC 1.1.1.40)两种。这两种酶各自由sfcA和b2463基因编码。
联用“Red-driven integration”法和切除系统方法缺失sfcA和b2463基因,“Red-driven integration”法最初由Datsenko和Wanner开发(Proc.Natl.Acad.Sci.USA,2000,97,6640-6645),切除系统方法来自λ噬菌体(J.Bacteriol.2002 Sep;184(18):5200-3.Interactions betweenintegrase和excisionase in the phage lambda excisive nucleoproteincomplex.Cho EH,Gumport RI,GardnerJF.)。依据“Red-drivenintegration”法,通过使用PCR产物一步就可构建基因破坏的菌株,该PCR产物通过使用合成的寡核苷酸引物获得,引物被设计为在5’端包含部分靶基因,在3’端包含部分抗生素抗性基因。此外,通过进一步联用来自λ噬菌体的切除系统与red-driven integration法,可去除整合的抗生素抗性基因。
(1)sfcA基因的破坏
使用质粒pMW118-attL-Cm-attR作为PCR模板(其制备如下描述)。将λ噬菌体的附着位点基因attL和attR以及cat基因(抗生素抗性基因)插入PMW118(TaKaRa Bio),获得pMW118-attL-Cm-attR。以attL-cat-attR的顺序插入这些基因。attL的序列显示于SEQ ID NO:5,attR序列显示于SEQ ID NO:6。
使用SEQ ID NO:1和2所示的引物进行PCR,并且引物具有对应于attL和attR 3’末端的序列,在5’末端具有对应于sfcA基因部分的序列。
在琼脂糖凝胶上纯化扩增的PCR产物,并通过电穿孔引入含有显示温度敏感型复制的质粒pKD46的大肠杆菌WC196。pKD46(Proc.Natl.Acad.Sci.USA,2000,97,6640-6645)包括λ噬菌体(GenBank/EMBL检索号J02459,31088-33241)的2,154nt DNA片段,含有在阿拉伯糖可诱导ParaB启动子控制下的编码λRed同源重组系统Red重组酶的基因(γ、β和核酸外切酶基因)。对于PCR产物整合入菌株WC196的染色体,pKD46是必需的。
用于电穿孔的感受态细胞如下制备。大肠杆菌WC196在含有100mg/l氨苄西林的LB培养基中30℃下培养过夜,使用5ml含有氨苄西林(50mg/l)和L-阿拉伯糖(1mM)的SOB培养基稀释100倍(Sambrook,J.等,"Molecular Cloning A Laboratory Manual,SecondEdition",Cold Spring Harbor Laboratory Press(1989))。稀释后的菌液在30℃下通气培养,直到OD600变为约0.6,然后浓缩100倍。使用10%甘油洗涤细胞三次以制备准备用于电穿孔的细胞。使用70μl感受态细胞和约100ng PCR产物进行电穿孔。向进行电穿孔的细胞添加1ml SOC培养基(Sambrook,J.等,"Molecular Cloning A LaboratoryManual,Second Edition",Cold Spring Harbor Laboratory Press(1989))。37℃下培养细胞2.5小时,然后37℃下平板培养于含有25mg/l Cm(氯霉素)的L-琼脂培养基上,以选择Cm抗性的重组体。然后,在含有Cm的L-琼脂培养基上42℃下传代培养2次以去除pKD46质粒。获得的菌落测试氨苄西林抗性。得到一株对氨苄西林敏感的不含有pKD46的菌株。
通过氯霉素抗性基因鉴定的缺失sfcA基因的突变体经PCR证实。所得的sfcA缺陷菌株被命名为WC196ΔsfcA::att-cat。
使用辅助质粒pMW-intxis-ts(其制备如下所述)清除整合入sfcA基因的att-cat基因。pMW-intxis-ts包含编码λ噬菌体整合酶的基因(Int)(SEQ ID NO:7)和编码切割酶的基因(Xis)(SEQ ID NO:9),并表现温度敏感性复制。通过引入pMW-intxis-ts,由于识别染色体上的attL(SEQ ID NO:5)和attR(SEQ ID NO:6)而发生重组,attL和attR之间的抗生素抗性基因被切除,导致只有attL或attR序列保留在染色体上的结构。
菌株WC196ΔsfcA::att-cat的感受态细胞按照常规方法制备,用辅助质粒pMW-intxis-ts转化,在含有50mg/l氨苄西林的L-琼脂培养基上30℃下平板培养,以选择氨苄西林抗性的菌株。
细胞于42℃下在L-琼脂培养基上传代培养两次以去除pMW-intxis-ts质粒。对获得的菌株测试氨苄西林抗性和氯霉素抗性。获得一株对氨苄西林和氯霉素敏感的无att-cat和pMW-intxis-ts的菌株。这株菌株被命名为WC196ΔsfcA。
(2)破坏b2463基因
依据方法(1),除了使用引物SEQ ID NO:3和4作为引物用于破坏b2463外,使菌株WC196和WC196ΔsfcA中的b2463缺失。因此,获得菌株WC196Δb2463和WC196ΔsfcAΔb2463。获得的菌株WC196ΔsfcAΔb2463被命名为WC196Δmez。
(3)制备PCR模板和辅助质粒
如下制备PCR模板pMW118-attL-Cm-attR和辅助质粒pMW-intxis-ts:
(3-1)pMW118-attL-Cm-attR
从pMW118-attL-Tc-attR出发构建质粒pMW118-attL-Cm-attR。连接以下4个DNA片段:
1)携带attL的BglII-EcoRI-DNA片段(120bp)(SEQ ID NO:5),其通过使用寡核苷酸P1和P2(SEQ ID NO:11和12)作为引物(这些引物含有BglII和EcoRI核酸内切酶的辅助识别位点),PCR扩增大肠杆菌W3350(含有λ噬菌体)染色体的相应序列获得;
2)携带attR的PstI-HindIII-DNA片段(182bp)(SEQ ID NO:6),其通过使用寡核苷酸P3和P4(SEQ ID NO:13和14)作为引物(这些引物含有PstI和HindIII核酸内切酶的辅助识别位点),PCR扩增大肠杆菌W3350(含有λ噬菌体)染色体的相应序列获得;
3)pMW118-ter_rrnB的BglII-HindIII大片段(3916bp)。通过连接三个DNA片段获得pMW118-ter_rrnB:
●携带pMW118的AatII-EcoRI pol片段的大片段(2359bp),使用EcoRI限制性核酸内切酶消化pMW118,使用DNA聚合酶I的Klenow片段处理,然后使用AatII限制性核酸内切酶消化;
●携带抗氨苄西林的bla基因(ApR)的pUC19的AatII-BglII小片段(1194bp),通过使用寡核苷酸P5和P6(SEQ ID NO:15和16)作为引物(这些引物含有AatII和BglII核酸内切酶的辅助识别位点),PCR扩增pUC19质粒的相应序列获得;
●转录终止子ter_rrnB的BglII-PstI pol小片段(363bp),通过使用寡核苷酸引物P7和P8(SEQ ID NO:17和18)作为引物(这些引物含有BglII和PstI核酸内切酶的辅助识别位点),PCR扩增大肠杆菌MG165染色体的相应区域获得;
4)pML-Tc-ter_thrL的EcoRI-PstI的小片段(1388bp)(SEQ ID NO
23),包括四环素抗性基因和转录终止子ter_thrL,pML-Tc-ter_thrL用以下方式获得:
●用XbaI和BamHI限制性内切酶消化pML-MSC(2001#5),然后连接大片段(3342bp)和携带终止子ter_thrL的XbaI-BamHI片段(68bp),该片段通过使用寡核苷酸引物P9和P10(SEQ IDNO:19和20)作为模引物(这些引物含有XbaI和BamHI核酸内切酶的辅助识别位点),PCR扩增大肠杆菌MG1655染色体的相应区域获得,这个反应的产物即为pML-ter_thrL质粒;
●然后用KpnI和XbaI限制性内切酶消化pML-ter_thrL,用DNA聚合酶I的Klenow片段处理后,与含有四环素抗性基因的pBR322的EcoRI-Van91I小片段(1317bp)连接(EcoRI和Van91I限制性内切酶消化pBR322,再用DNA聚合酶I的Klenow片段处理得到),该反应产物为质粒pML-Tc-ter_thrL;
如此即获得pMW118-attL-Tc-attR。
将pMW118-attL-Tc-attR的BamHI-XbaI大片段(4413bp)与包含PA2启动子(T7噬菌体的早期启动子)、氯霉素抗性(CmR)的cat基因、转录终止子ter_thrL和attR的BglII-XbaI人工DNA片段(1162bp)连接,构建pMW118-attL-Cm-attR。该人工DNA片段(SEQ ID NO:24)按以下方法制备:
1.使用KpnI和XbaI限制性核酸内切酶消化pML-MSC(2001#5),并与包括启动子PA2(噬菌体T7的早期启动子)的KpnI-XbaI小片段(120bp)连接,该片段通过以寡核苷酸P11和P12(SEQ ID NO:21和22)为引物(这些引物含有KpnI和XbaI核酸内切酶的辅助识别位点),PCR扩增噬菌体T7DNA的相应区域获得,该反应的产物为质粒pML-PA2-MCS;
2.然后从pML-PA2-MCS缺失XbaI位点,该反应的产物为质粒pML-PA2-MCS(XbaI-);
3.然后将pML-PA2-MCS(XbaI-)的BglII-HindIII小片段(928bp)(其包含启动子PA2(噬菌体T7的早期启动子)和氯霉素抗性cat基因(CmR))与包含转录终止子ter_thrL和attR的pMW118-attL-Tc-attR的HindIII-HindIII小片段(234bp)连接;
4.使用寡核苷酸P9和P4(SEQ ID NO:19和14)作为引物(这些引物含有HindIII和XbaI核酸内切酶的辅助识别位点),通过PCR扩增连接反应的混合物,获得需要的人工DNA片段(1156bp)。
(3-2)pMW-intxis-ts
首先,使用λ噬菌体DNA(“Fermentas”)作为模板,扩增两种DNA片段。第一种片段包括nt 37168-38046(SEQ ID NO:33)的区域,并且也包含编码cI阻遏物、启动子Prm和Pr的基因,以及cro基因的前导序列。使用P1’和P2’寡核苷酸(SEQ ID NO:25和26)作为引物获得这个片段。第二种片段带有λ噬菌体的xis-int基因,并包含nt27801-29100(SEQ ID NO:34)的区域。寡核苷酸P3’和P4’(SEQ ID NO:27和28)作为引物用于它的扩增。所有的引物都含有合适的核酸内切酶识别位点。
获得的携带cI阻遏物的PCR扩增片段使用限制性核酸内切酶ClaI消化,用DNA聚合酶I的Klenow片段处理,然后使用EcoRI限制性核酸内切酶消化。第二种PCR扩增片段使用EcoRI和PstI限制性核酸内切酶消化。然后使用BglII核酸内切酶消化pMWPlaclacI-ts质粒,使用DNA聚合酶I的Klenow片段处理,然后使用PstI限制性核酸内切酶消化。从琼脂糖凝胶中洗脱出pMWPlaclacI-ts的载体片段,与消化的PCR扩增片段连接。
质粒pMWPlaclacI-ts是pMWPlaclacI的衍生物,由以下部分组成:1)BglII-HindIII-人工DNA片段,其包括在Placuv5启动子控制下的lacI基因和T7噬菌体10号基因的RBS;2)携带氨苄西林抗性基因(ApR)的AatII-BglII-DNA片段,其通过使用寡核苷酸P5’和P6’(SEQID NO:29和30)作为引物(这些引物含有AatII和BglII核酸内切酶的辅助识别位点),PCR扩增pUC19质粒的相应序列获得;3)AatII-HindIII-片段,其包含先前构建的重组质粒pMW118-ter_rrnB的AatII-PvuI片段。后一质粒按以下方式构建:使用含有合适核酸内切酶识别位点的寡核苷酸P7’和P8’(SEQ ID NO:31和32)作为引物,通过PCR扩增大肠杆菌MG1655染色体的相应区域,获得携带终止子ter_rrnB的PstI-HindIII DNA片段。在连接之前,使用PvuI或PstI核酸内切酶各自限制性消化pMW118质粒和ter_rrnB DNA片段(互补物,SEQ ID NO:35),使用DNA聚合酶I的Klenow片段处理以获得平末端,然后使用AatII或HindIII核酸内切酶限制性消化。为构建pMWPlaclacI-ts变体,用质粒pMAN997的AatII-EcoRV片段取代pMWPlaclacI质粒的AatII-EcoRV片段,前一AatII-EcoRV片段包含pSC101复制子的基因座par、ori和repAts基因。
实施例4
构建苹果酸酶缺陷的L-苏氨酸生产菌株
从菌株VKPM B-5318构建sfcA-和b2463-缺陷的菌株。该VKPMB-5318菌株在1989年11月19日保藏在俄罗斯国立工业微生物收藏中心(VKPM,GNII Genetika),检索号VKPM B-5318。
用与实施例3中相同的方式,使用“Red-driven integration”法,获得一株苹果酸酶(mez)基因(sfcA,b2463)缺陷的菌株。即,使用与实施例3中相同的“Red-driven integration”法,除了使用菌株B-5318而不是菌株WC196以外,获得sfcA-或b2463-缺陷的菌株突变体,其由氯霉素抗性基因鉴定。破坏sfcA的菌株B-5318被命名为B-5318ΔsfcA。破坏b2463的菌株被命名为B-5318Δb2463。以与实施例3中相同的方式,使用“Red-driven integration”和切除系统方法,获得具有已破坏sfcA和b2463基因的菌株B-5318,B-5318ΔsfcAΔb2463。菌株B-5318ΔsfcAΔb2463被命名为B-5318Δmez。
实施例5
评价苹果酸酶缺陷的菌株
<5-1>评价b2463缺陷的L-苏氨酸生产菌株
菌株B-5318Δb2463和B-5318各自培养于含有20mg/L硫酸链霉素和25mg/L硫酸卡那霉素的LB琼脂培养基(10g/L胰蛋白胨、5g/L酵母提取物、5g/L氯化钠和15g/L琼脂)上,37℃下培养24小时,将平板上的1/5细菌细胞接种于含有20mg/L硫酸链霉素和25mg/L硫酸卡那霉素的50ml LB液体培养基(10g/L胰蛋白胨、5g/L酵母提取物和5g/L氯化钠),40℃、144rpm下预培养3.5小时。
在完成预培养之后,预培养菌液被接种入装有300ml主培养基的1L发酵罐中,接种量为主培养基的10%体积,40℃和pH 7.0下进行主培养。主培养基的组分如下所示:
表4
主培养基的组分
葡萄糖 100g/L
酵母提取物 1.8g/L
FeSO4·7H2O 18mg/L
MnSO4·4H2O 18mg/L
KH2PO4 1.0g/L
MgSO4·7H2O 0.36g/L
(NH4)2SO4 4.5g/L
NaCl 0.6g/L
硫酸链霉素 20mg/L
硫酸卡那霉素 25mg/L
在培养期间通过加入氨气调节pH至7.0。
待加入的糖消耗后,通过液相色谱测量L-苏氨酸的量。结果显示于表5中。
当使用b2463缺陷的菌株B-5318Δb2463时,与对照菌株B-5318相比苏氨酸的产率增加。
表5
菌株 | L-苏氨酸的发酵产率(%) |
B-5318B-5318Δb2463 | 31.432.1 |
<5-2>评价sfcA缺陷的L-苏氨酸生产菌株
以与<5-1>相同的方式培养菌株B-5318ΔsfcA和B5318。
待加入的糖消耗后,通过液相色谱测量L-苏氨酸量。结果显示于表6中。
当使用b2463-缺陷的菌株B-5318ΔsfcA时,与对照菌株B-5318相比苏氨酸的产率增加。
表6
菌株 | L-苏氨酸的发酵产率(%) |
B-5318B-5318ΔsfcA | 31.432.2 |
<5-3>评价sfcA和b2463缺陷的L-赖氨酸生产菌株
依据常规方法,使用用于赖氨酸生产的包含dapA、dapB和dapC基因的质粒pCABD2(国际公开号WO01/53459)转化菌株WC196、WC196ΔsfcA和WC196Δb2463,以获得菌株WC196/pCABD2、WC196ΔsfcA/pCABD2和WC196Δb2463/pCABD2。
将菌株WC196/pCABD2、WC196ΔsfcA/pCABD2和WC196Δb2463/pCABD2在37℃下培养于含有20mg/L链霉素的L培养基(如下描述),直到培养基的OD600为约0.6。然后,向培养物中添加与培养物等量的40%甘油溶液。搅拌之后,将混合物分成合适等分,保藏于-80℃。保藏的等分被称为为甘油原液。
解冻菌株的甘油原液,每100μl均匀涂布于含有20mg/L链霉素的L平板上,并37℃下培养24小时。从获得平板的1/8上获取细菌细胞,接种于20mL含有20mg/L链霉素的发酵培养基(如下描述),37℃下摇床培养约16小时。培养之后,通过Biotech Analyzer AS210(Sakura Seiki)测量累积在培养基中的赖氨酸量和残留的葡萄糖量。
累积的L-赖氨酸和扣除细胞后的产率的结果显示在表7中。扣除细胞后的产率是通过扣除用于细菌细胞形成的糖量而计算的产率,其计算基于假设消耗掉糖的50%用于形成细菌细胞。从结果中看出,与对照菌株WC196/pCABD2相比,菌株WC196ΔsfcA/pCABD2和WC196Δb2463/pCABD2的细胞扣除产率增加。
表7
用于评价sfcA或b2463缺陷的L-赖氨酸生产菌株的培养基如下描述。使用的试剂从Wako Pure Chemicals或Nakarai Tesque获得,除非另有说明。使用的培养基组分显示如下。使用NaOH或HCl调节所有培养基的pH。
表8
(L培养基)
细菌用胰蛋白胨(DIFCO) 10g/L
酵母提取物(DIFCO) 5g/L
NaCl 5g/L
pH 7.0
[120℃下蒸气灭菌20分钟]
(L琼脂培养基)
L培养基
细菌用琼脂(DIFCO) 15g/L
[120℃下蒸气灭菌20分钟]
(大肠杆菌的L-赖氨酸生产培养基)
葡萄糖 40g/L
硫酸铵 24g/L
磷酸二氢钾 1.0g/L
七水合硫酸镁 1.0g/L
七水合硫酸亚铁(II) 0.01g/L
四水合硫酸锰 0.01g/L
酵母提取物 2.0g/L
碳酸钙(药典) 30g/L
[使用氢氧化钾调节至pH 7.0,115℃下蒸气灭菌10分钟,前提条件是葡萄糖和MgSO4·7H2O分开灭菌]
实施例6
评价苹果酸酶缺陷的菌株(Δmez)
<6-1>评价苹果酸酶缺陷的L-苏氨酸生产菌株
将菌株B-5318Δmez和B-5318各自在含有20mg/L硫酸链霉素和25mg/L硫酸卡那霉素的LB琼脂培养基(10g/L胰蛋白胨、5g/L酵母提取物、5g/L NaCl和15g/L琼脂)上37℃下培养24小时,从一个平板上获取细菌细胞,悬浮于5ml LB液体培养基中(10g/L胰蛋白胨、5g/L酵母提取物和5g/L NaCl)。将0.5ml悬液接种于50ml含有20mg/L硫酸链霉素和25mg/L硫酸卡那霉素的LB液体培养基,39℃、144rpm下预培养4小时。
完成预培养后,预培养菌液接种入装有300ml主培养基的1L发酵罐中,接种量为主培养基的10%体积,在39℃和pH7.0进行主培养。主培养基组分如下所示:
表9
[主培养基组分]
葡萄糖 27g/L
酵母提取物 1.8g/L
FeSO4·7H2O 18mg/L
MnSO4·4H2O 18mg/L
KH2PO4 1.5g/L
MgSO4·7H2O 0.36g/L
(NH4)2SO4 4.5g/L
NaCl 0.6g/L
硫酸链霉素 20mg/L
硫酸卡那霉素 25mg/L
在培养期间通过添加氨气调节pH至7.0。
待加入的糖消耗和耗尽后,添加600g/l葡萄糖水溶液。
主培养24小时之后,通过液相色谱测量L-苏氨酸的量。结果显示于表10中。
当使用苹果酸酶缺陷的菌株B-5318Δmez时,与对照菌株B-5318相比苏氨酸的产率增加。
表10
菌株 | L-苏氨酸的发酵产率 |
B-5318B-5318Δmez | 35.938.3 |
<6-2>评价苹果酸酶缺陷的L-赖氨酸生产菌株
依据常规方法使用用于赖氨酸生产的质粒pCABD2(国际公开号WO 01/53459)转化菌株WC196和WC196Δmez,以获得菌株WC196/pCABD2和WC196Δmez/pCABD2。
将菌株WC196/pCABD2和WC196Δmez/pCABD2在37℃下培养于含有20mg/L链霉素的L培养基(同实施例5<5-3>中使用的),直到培养基的OD600变为约0.6。然后,向培养物中添加与培养物等量的40%甘油溶液。搅拌之后,将混合物分成合适等分,保藏于-80℃。保藏的等分被称为为甘油原液。
解冻菌株的甘油原液,每100μl均匀涂布于含有20mg/L链霉素的L平板上,并37℃下培养24小时。从获得平板的1/8上获取细菌细胞,接种于20mL含有20mg/L链霉素的发酵培养基(同实施例5<5-3>中使用的),37℃下摇床培养约48小时。培养之后,通过BiotechAnalyzer AS210(Sakura Seiki)测量累积在培养基中的赖氨酸量和残留的葡萄糖量。
累积的L-赖氨酸和扣除细胞后的产率的结果显示在表11中。基于假设消耗的糖的50%用于形成细菌细胞,计算扣除细胞后的产率。从结果中看出,与对照菌株WC196/pCABD2相比,菌株WC196Δmez/pCABD2的扣除细胞后的产率增加。
表11
工业实用性
依据本发明,可有效测定影响物质生产的代谢流量,因此可提供改进细菌的指导。此外,也可提供基于这种指导改进细菌菌株的方法。
<110>味之素株式会社(Ajinomoto Co.,Inc.)
<120>影响物质生产的代谢流量的测定方法
<130>C2500PC4076
<150>JP 2003-202842
<151>2003-07-29
<160>35
<210>1
<211>54
<212>DNA
<213>人工序列
<220>
<223>引物
<400>1
aatatctttc agttccggca gtaccatacc ttcgcctgaa gcctgctttt ttat 54
<210>2
<211>54
<212>DNA
<213>人工序列
<220>
<223>引物
<400>2
agcatggaag aacgccgtaa cttcaacctg ctggggcgct caagttagta taaa 54
<210>3
<211>54
<212>DNA
<213>人工序列
<220>
<223>引物
<400>3
cgacgggcag tcagaagaac caaagttgga gtgcgatgaa gcctgctttt ttat 54
<210>4
<211>54
<212>DNA
<213>人工序列
<220>
<223>引物
<400>4
gacattgaag ttgacgaact cgacccggac aaatttcgct caagttagta taaa 54
<210>5
<211>120
<212>DNA
<213>λ噬菌体
<400>5
agatcttgaa gcctgctttt ttatactaag ttggcattat aaaaaagcat tgcttatcaa 60
tttgttgcaa cgaacaggtc actatcagtc aaaataaaat cattatttga tttcgaattc 120
<210>6
<211>184
<212>DNA
<213>λ噬菌体
<400>6
ctgcagtctg ttacaggtca ctaataccat ctaagtagtt gattcatagt gactgcatat 60
gttgtgtttt acagtattat gtagtctgtt ttttatgcaa aatctaattt aatatattga 120
tatttatatc attttacgtt tctcgttcag cttttttata ctaacttgag cgtctagaaa 180
gctt 184
<210>7
<211>1071
<212>DNA
<213>λ噬菌体
<220>
<221>CDS
<222>(1)..(1071)
<400>7
atg gga aga agg cga agt cat gag cgc cgg gat tta ccc cct aac ctt 48
Met Gly Arg Arg Arg Ser His Glu Arg Arg Asp Leu Pro Pro Asn Leu
1 5 10 15
tat ara aga aac aat gga tat tac tgc tac agg gac cca agg acg ggt 96
Tyr Ile Arg Asn Asn Gly Tyr Tyr Cys Tyr Arg Asp Pro Arg Thr Gly
20 25 30
aaa gag ttt gga tta ggc aga gac agg cga atc gca atc act gaa gct 144
Lys Glu Phe Gly Leu Gly Arg Asp Arg Arg Ile Ala Ile Thr Glu Ala
35 40 45
ata cag gcc aac att gag tta ttt tca gga cac aaa cac aag cct ctg 192
Ile Gln Ala Asn Ile Glu Leu Phe Ser Gly His Lys His Lys Pro Leu
50 55 60
aca gcg aga atc aac agt gat aat tcc gtt acg tta cat tca tgg ctt 240
Thr Ala Arg Ile Asn Ser Asp Asn Ser Val Thr Leu His Ser Trp Leu
65 70 75 80
gat cgc tac gaa aaa atc ctg gcc agc aga gga atc aag cag aag aca 288
Asp Arg Tyr Glu Lys Ile Leu Ala Ser Arg Gly Ile Lys Gln Lys Thr
85 90 95
ctc ata aat tac atg agc aaa att aaa gca ata agg agg ggt ctg cct 336
Leu Ile Asn Tyr Met Ser Lys Ile Lys Ala Ile Arg Arg Gly Leu Pro
100 105 110
gat gct cca ctt gaa gac atc acc aca aaa gaa att gcg gca atg ctc 384
Asp Ala Pro Leu Glu Asp Ile Thr Thr Lys Glu Ile Ala Ala Met Leu
115 120 125
aat gga tac ata gac gag ggc aag gcg gcg tca gcc aag tta atc aga 432
Asn Gly Tyr Ile Asp Glu Gly Lys Ala Ala Ser Ala Lys Leu Ile Arg
130 135 140
tca aca ctg agc gat gca ttc cga gag gca ata gct gaa ggc cat ata 480
Ser Thr Leu Ser Asp Ala Phe Arg Glu Ala Ile Ala Glu Gly His Ile
145 150 155 160
aca aca aac cat gtc gct gcc act cgc gca gca aaa tca gag gta agg 528
Thr Thr Asn His Val Ala Ala Thr Arg Ala Ala Lys Ser Glu Val Arg
165 170 175
aga tca aga ctt acg gct gac gaa tac ctg aaa att tat caa gca gca 576
Arg Ser Arg Leu Thr Ala Asp Glu Tyr Leu Lys Ile Tyr Gln Ala Ala
180 185 190
gaa tca tca cca tgt tgg ctc aga ctt gca atg gaa ctg gct gtt gtt 624
Glu Ser Ser Pro Cys Trp Leu Arg Leu Ala Met Glu Leu Ala Val Val
195 200 205
acc ggg caa cga gtt ggt gat tta tgc gaa atg aag tgg tct gat atc 672
Thr Gly Gln Arg Val Gly Asp Leu Cys Glu Met Lys Trp Ser Asp Ile
210 215 220
gta gat gga tat ctt tat gtc gag caa agc aaa aca ggc gta aaa att 720
Val Asp Gly Tyr Leu Tyr Val Glu Gln Ser Lys Thr Gly Val Lys Ile
225 230 235 240
gcc atc cca aca gca ttg cat att gat gct ctc gga ata tca atg aag 768
Ala Ile Pro Thr Ala Leu His Ile Asp Ala Leu Gly Ile Ser Met Lys
245 250 255
gaa aca ctt gat aaa tgc aaa gag att ctt ggc gga gaa acc ata att 816
Glu Thr Leu Asp Lys Cys Lys Glu Ile Leu Gly Gly Glu Thr Ile Ile
260 265 270
gca tct act cgt cgc gaa ccg ctt tca tcc ggc aca gta tca agg tat 864
Ala Ser Thr Arg Arg Glu Pro Leu Ser Ser Gly Thr Val Ser Arg Tyr
275 280 285
ttt atg cgc gca cga aaa gca tca ggt ctt tcc ttc gaa ggg gat ccg 912
Phe Met Arg Ala Arg Lys Ala Ser Gly Leu Ser Phe Glu Gly Asp Pro
290 295 300
cct acc ttt cac gag ttg cgc agt ttg tct gca aga ctc tat gag aag 960
Pro Thr Phe His Glu Leu Arg Ser Leu Ser Ala Arg Leu Tyr Glu Lys
305 310 315 320
cag ata agc gat aag ttt gct caa cat ctt ctc ggg cat aag tcg gac 1008
Gln Ile Ser Asp Lys Phe Ala Gln His Leu Leu Gly His Lys Ser Asp
325 330 335
acc atg gca tca cag tat cgt gat gac aga ggc agg gag tgg gac aaa 1056
Thr Met Ala Ser Gln Tyr Arg Asp Asp Arg Gly Arg Glu Trp Asp Lys
340 345 350
att gaa atc aaa taa 1071
Ile Glu Ile Lys
355
<210>8
<211>356
<212>PRT
<213>λ噬菌体
<400>8
Met Gly Arg Arg Arg Ser His Glu Arg Arg Asp Leu Pro Pro Asn Leu
1 5 10 15
Tyr Ile Arg Asn Asn Gly Tyr Tyr Cys Tyr Arg Asp Pro Arg Thr Gly
20 25 30
Lys Glu Phe Gly Leu Gly Arg Asp Arg Arg Ile Ala Ile Thr Glu Ala
35 40 45
Ile Gln Ala Asn Ile Glu Leu Phe Ser Gly His Lys His Lys Pro Leu
50 55 60
Thr Ala Arg Ile Asn Ser Asp Asn Ser Val Thr Leu His Ser Trp Leu
65 70 75 80
Asp Arg Tyr Glu Lys Ile Leu Ala Ser Arg Gly Ile Lys Gln Lys Thr
85 90 95
Leu Ile Asn Tyr Met Ser Lys Ile Lys Ala Ile Arg Arg Gly Leu Pro
100 105 110
Asp Ala Pro Leu Glu Asp Ile Thr Thr Lys Glu Ile Ala Ala Met Leu
115 120 125
Asn Gly Tyr Ile Asp Glu Gly Lys Ala Ala Ser Ala Lys Leu Ile Arg
130 135 140
Ser Thr Leu Ser Asp Ala Phe Arg Glu Ala Ile Ala Glu Gly His Ile
145 150 155 160
Thr Thr Asn His Val Ala Ala Thr Arg Ala Ala Lys Ser Glu Val Arg
165 170 175
Arg Ser Arg Leu Thr Ala Asp Glu Tyr Leu Lys Ile Tyr Gln Ala Ala
180 185 190
Glu Ser Ser Pro Cys Trp Leu Arg Leu Ala Met Glu Leu Ala Val Val
195 200 205
Thr Gly Gln Arg Val Gly Asp Leu Cys Glu Met Lys Trp Ser AspIle
210 215 220
Val Asp Gly Tyr Leu Tyr Val Glu Gln Ser Lys Thr Gly Val Lys Ile
225 230 235 240
Ala Ile Pro Thr Ala Leu His Ile Asp Ala Leu Gly Ile Ser Met Lys
245 250 255
Glu Thr Leu Asp Lys Cys Lys Glu Ile Leu Gly Gly Glu Thr Ile Ile
260 265 270
Ala Ser Thr Arg Arg Glu Pro Leu Ser Ser Gly Thr Val Ser Arg Tyr
275 280 285
Phe Met Arg Ala Arg Lys Ala Ser Gly Leu Ser Phe Glu Gly Asp Pro
290 295 300
Pro Thr Phe His Glu Leu Arg Ser Leu Ser Ala Arg Leu Tyr Glu Lys
305 310 315 320
Gln Ile Ser Asp Lys Phe Ala Gln His Leu Leu Gly His Lys Ser Asp
325 330 335
Thr Met Ala Ser Gln Tyr Arg Asp Asp Arg Gly Arg Glu Trp Asp Lys
340 345 350
Ile Glu Ile Lys
355
<210>9
<211>219
<212>DNA
<213>λ噬菌体
<220>
<221>CDS
<222>(1)..(219)
<400>9
atg tac ttg aca ctt cag gag tgg aac gca cgc cag cga cgt cca aga 48
Met Tyr Leu Thr Leu Gln Glu Trp Asn Ala Arg Gln Arg Arg Pro Arg
1 5 10 15
agc ctt gaa aca gtt cgt cga tgg gtt cgg gaa tgc agg ata ttc cca 96
Ser Leu Glu Thr Val Arg Arg Trp Val Arg Glu Cys Arg Ile Phe Pro
20 25 30
cct ccg gtt aag gat gga aga gag tat ctg ttc cac gaa tca gcg gta 144
Pro Pro Val Lys Asp Gly Arg Glu Tyr Leu Phe His Glu Ser Ala Val
35 40 45
aag gtt gac tta aat cga cca gta aca ggt ggc ctt ttg aag agg atc 192
Lys Val Asp Leu Asn Arg Pro Val Thr Gly Gly Leu Leu Lys Arg Ile
50 55 60
aga aat ggg aag aag gcg aag tca tga 219
Arg Asn Gly Lys Lys Ala Lys Ser
65 70
<210>10
<211>72
<212>PRT
<213>λ噬菌体
<400>10
Met Tyr Leu Thr Leu Gln Glu Trp Asn Ala Arg Gln Arg Arg Pro Arg
1 5 10 15
Ser Leu Glu Thr Val Arg Arg Trp Val Arg Glu Cys Arg Ile Phe Pro
20 25 30
Pro Pro Val Lys Asp Gly Arg Glu Tyr Leu Phe His Glu Ser Ala Val
35 40 45
Lys Val Asp Leu Asn Arg Pro Val Thr Gly Gly Leu Leu Lys Arg Ile
50 55 60
Arg Asn Gly Lys Lys Ala Lys Ser
65 70
<2l0>11
<211>40
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P1
<400>11
ctagtaagat cttgaagcct gcttttttat actaagttgg 40
<210>12
<211>41
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P2
<400>12
atgatcgaat tcgaaatcaa ataatgattt tattttgact g 41
<210>13
<211>41
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P3
<400>13
atgccactgc agtctgttac aggtcactaa taccatctaa g 41
<210>14
<211>46
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P4
<400>14
accgttaagc tttctagacg ctcaagttag tataaaaaag ctgaac 46
<210>15
<211>38
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P5
<400>15
ttcttagacg tcaggtggca cttttcgggg aaatgtgc 38
<210>16
<211>37
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P6
<400>16
taacagagat ctcgcgcaga aaaaaaggat ctcaaga 37
<210>17
<211>46
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P7
<400>17
aacagagatc taagcttaga tcctttgcct ggcggcagta gcgcgg 46
<210>18
<211>35
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P8
<400>18
ataaactgca gcaaaaagag tttgtagaaa cgcaa 35
<210>19
<211>36
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P9
<400>19
agtaattcta gaaagcttaa cacagaaaaa agcccg 36
<210>20
<211>43
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P10
<400>20
ctagtaggat ccctgcagtg gtcgaaaaaa aaagcccgca ctg 43
<210>21
<211>37
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P11
<400>21
atcgaggtac cagatctccg gataagtaga cagcctg 37
<210>22
<211>32
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P12
<400>22
gaaggtctag agcgcccggt tgacgctgct ag 32
<210>23
<211>1388
<212>DNA
<213>人工序列
<220>
<223>克隆的DNA片段EcoRI-PstI,包含四环素抗性基因(pBR322的小EcoRI-Van91I片段)和转录终止子ter_thrL
<400>23
gaattctcat gtttgacagc ttatcatcga taagctttaa tgcggtagtt tatcacagtt 60
aaattgctaa cgcagtcagg caccgtgtat gaaatctaac aatgcgctca tcgtcatcct 120
cggcaccgtc accctggatg ctgtaggcat aggcttggtt atgccggtac tgccgggcct 180
cttgcgggat atcgtccatt ccgacagcat cgccagtcac tatggcgtgc tgctagcgct 240
atatgcgttg atgcaatttc tatgcgcacc cgttctcgga gcactgtccg accgctttgg 300
ccgccgccca gtcctgctcg cttcgctact tggagccact atcgactacg cgatcatggc 360
gaccacaccc gtcctgtgga tcctctacgc cggacgcatc gtggccggca tcaccggcgc 420
cacaggtgcg gttgctggcg cctatatcgc cgacatcacc gatggggaag atcgggctcg 480
ccacttcggg ctcatgagcg cttgtttcgg cgtgggtatg gtggcaggcc ccgtggccgg 540
gggactgttg ggcgccatct ccttgcatgc accattcctt gcggcggcgg tgctcaacgg 600
cctcaaccta ctactgggct gcttcctaat gcaggagtcg cataagggag agcgtcgacc 660
gatgcccttg agagccttca acccagtcag ctccttccgg tgggcgcggg gcatgactat 720
cgtcgccgca cttatgactg tcttctttat catgcaactc gtaggacagg tgccggcagc 780
gctctgggtc attttcggcg aggaccgctt tcgctggagc gcgacgatga tcggcctgtc 840
gcttgcggta ttcggaatct tgcacgccct cgctcaagcc ttcgtcactg gtcccgccac 900
caaacgtttc ggcgagaagc aggccattat cgccggcatg gcggccgacg cgctgggcta 960
cgtcttgctg gcgttcgcga cgcgaggctg gatggccttc cccattatga ttcttctcgc 1020
ttccggcggc atcgggatgc ccgcgttgca ggccatgctg tccaggcagg tagatgacga 1080
ccatcaggga cagcttcaag gatcgctcgc ggctcttacc agcctaactt cgatcactgg 1140
accgctgatc gtcacggcga tttatgccgc ctcggcgagc acatggaacg ggttggcatg 1200
gattgtaggc gccgccctat accttgtctg cctccccgcg ttgcgtcgcg gtgcatggag 1260
ccgggccacc tcgacctgaa tggaagccgg cggcacctcg ctaacggatt caccactcca 1320
actagaaagc ttaacacaga aaaaagcccg cacctgacag tgcgggcttt ttttttcgac 1380
cactgcag 1388
<210>24
<211>1162
<212>DNA
<213>人工序列
<220>
<223>包含人工DNA片段的克隆DNA片段,包含启动子PA2(噬菌体T7的早期启动子)、氯霉素抗性cat基因(CmR)、转录终止子ter_thrL和attR
<400>24
agatctccgg ataagtagac agcctgataa gtcgcacgaa aaacaggtat tgacaacatg 60
aagtaacatg cagtaagata caaatcgcta ggtaacacta gcagcgtcaa ccgggcgctc 120
tagctagagc caagctagct tggccggatc cgagattttc aggagctaag gaagctaaaa 180
tggagaaaaa aatcactgga tataccaccg ttgatatatc ccaatggcat cgtaaagaac 240
attttgaggc atttcagtca gttgctcaat gtacctataa ccagaccgtt cagctggata 300
ttacggcctt tttaaagacc gtaaagaaaa ataagcacaa gttttatccg gcctttattc 360
acattcttgc ccgcctgatg aatgctcatc cggaattccg tatggcaatg aaagacggtg 420
agctggtgat atgggatagt gttcaccctt gttacaccgt tttccatgag caaactgaaa 480
cgttttcatc gctctggagt gaataccacg acgatttccg gcagtttcta cacatatatt 540
cgcaagatgt ggcgtgttac ggtgaaaacc tggcctattt ccctaaaggg tttattgaga 600
atatgttttt cgtctcagcc aatccctggg tgagtttcac cagttttgat ttaaacgtgg 660
ccaatatgga caacttcttc gcccccgttt tcaccatggg caaatattat acgcaaggcg 720
acaaggtgct gatgccgctg gcgattcagg ttcatcatgc cgtctgtgat ggcttccatg 780
tcggcagaat gcttaatgaa ttacaacagt actgcgatga gtggcagggc ggggcgtaat 840
ttttttaagg cagttattgg tgcccttaaa cgcctggtgc tacgcctgaa taagtgataa 900
taagcggatg aatggcagaa attcgtcgaa gcttaacaca gaaaaaagcc cgcacctgac 960
agtgcgggct ttttttttcg accactgcag tctgttacag gtcactaata ccatctaagt 1020
agttgattca tagtgactgc atatgttgtg ttttacagta ttatgtagtc tgttttttat 1080
gcaaaatcta atttaatata ttgatattta tatcatttta cgtttctcgt tcagcttttt 1140
tatactaact tgagcgtcta ga 1162
<210>25
<211>27
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P1’
<400>25
ctaatatcga tgaagattct tgctcaa 27
<210>26
<211>34
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P2’
<400>26
gcgttgaatt ccatacaacc tccttagtac atgc 34
<210>27
<211>34
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P3’
<400>27
gtactagaat tcgtgtaatt gcggagactt tgcg 34
<210>28
<211>41
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P4’
<400>28
aatagcctgc agttatttga tttcaatttt gtcccactcc c 41
<210>29
<211>38
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P5’
<400>29
ttcttagacg tcaggtggca cttttcgggg aaatgtgc 38
<210>30
<211>37
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P6’
<400>30
taacagagat ctagcgcaga aaaaaaggat ctcaaga 37
<210>31
<211>35
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P7’
<400>31
ataaactgca gcaaaaagag tttgtagaaa cgcaa 35
<210>32
<211>34
<212>DNA
<213>人工序列
<220>
<223>寡核苷酸P8’
<400>32
aacagaagct ttttgcctgg cggcagtagc gcgg 34
<210>33
<211>879
<212>DNA
<213>人工序列
<220>
<223>克隆的DNA片段,包含cI抑制基因和启动子区
<400>33
tcgatgaaga ttcttgctca attgttatca gctatgcgcc gaccagaaca ccttgccgat 60
cagccaaacg tctcttcagg ccactgacta gcgataactt tccccacaac ggaacaactc 120
tcattgcatg ggatcattgg gtactgtggg tttagtggtt gtaaaaacac ctgaccgcta 180
tccctgatca gtttcttgaa ggtaaactca tcacccccaa gtctggctat gcagaaatca 240
cctggctcaa cagcctgctc agggtcaacg agaattaaca ttccgtcagg aaagcttggc 300
ttggagcctg ttggtgcggt catggaatta ccttcaacct caagccagaa tgcagaatca 360
ctggcttttt tggttgtgct tacccatctc tccgcatcac ctttggtaaa ggttctaagc 420
tcaggtgaga acatccctgc ctgaacatga gaaaaaacag ggtactcata ctcacttcta 480
agtgacggct gcatactaac cgcttcatac atctcgtaga tttctctggc gattgaaggg 540
ctaaattctt caacgctaac tttgagaatt tttgcaagca atgcggcgtt ataagcattt 600
aatgcattga tgccattaaa taaagcacca acgcctgact gccccatccc catcttgtct 660
gcgacagatt cctgggataa gccaagttca tttttctttt tttcataaat tgctttaagg 720
cgacgtgcgt cctcaagctg ctcttgtgtt aatggtttct tttttgtgct catacgttaa 780
atctatcacc gcaagggata aatatctaac accgtgcgtg ttgactattt tacctctggc 840
ggtgataatg gttgcatgta ctaaggaggt tgtatggaa 879
<210>34
<211>1290
<212>DNA
<213>人工序列
<220>
<223>克隆的DNA片段,包含int-xis基因
<400>34
attatttgat ttcaattttg tcccactccc tgcctctgtc atcacgatac tgtgatgcca 60
tggtgtccga cttatgcccg agaagatgtt gagcaaactt atcgcttatc tgcttctcat 120
agagtcttgc agacaaactg cgcaactcgt gaaaggtagg cggatcccct tcgaaggaaa 180
gacctgatgc ttttcgtgcg cgcataaaat accttgatac tgtgccggat gaaagcggtt 240
cgcgacgagt agatgcaatt atggtttctc cgccaagaat ctctttgcat ttatcaagtg 300
tttccttcat tgatattccg agagcatcaa tatgcaatgc tgttgggatg gcaattttta 360
cgcctgtttt gctttgctcg acataaagat atccatctac gatatcagac cacttcattt 420
cgcataaatc accaactcgt tgcccggtaa caacagccag ttccattgca agtctgagcc 480
aacatggtga tgattctgct gcttgataaa ttttcaggta ttcgtcagcc gtaagtcttg 540
atctccttac ctctgatttt gctgcgcgag tggcagcgac atggtttgtt gttatatggc 600
cttcagctat tgcctctcgg aatgcatcgc tcagtgttga tctgattaac ttggctgacg 660
ccgccttgcc ctcgtctatg tatccattga gcattgccgc aatttctttt gtggtgatgt 720
cttcaagtgg agcatcaggc agacccctcc ttattgcttt aattttgctc atgtaattta 780
tgagtgtctt ctgcttgatt cctctgctgg ccaggatttt ttcgtagcga tcaagccatg 840
aatgtaacgt aacggaatta tcactgttga ttctcgctgt cagaggcttg tgtttgtgtc 900
ctgaaaataa ctcaatgttg gcctgtatag cttcagtgat tgcgattcgc ctgtctctgc 960
ctaatccaaa ctctttaccc gtccttgggt ccctgtagca gtaatatcca ttgtttctta 1020
tataaaggtt agggggtaaa tcccggcgct catgacttcg ccttcttccc atttctgatc 1080
ctcttcaaaa ggccacctgt tactggtcga tttaagtcaa cctttaccgc tgattcgtgg 1140
aacagatact ctcttccatc cttaaccgga ggtgggaata tcctgcattc ccgaacccat 1200
cgacgaactg tttcaaggct tcttggacgt cgctggcgtg cgttccactc ctgaagtgtc 1260
aagtacatcg caaagtctcc gcaattacac 1290
<210>35
<211>351
<212>DNA
<213>人工序列
<220>
<223>ter_rrnB片段(互补物)
<400>35
caaaaagagt ttgtagaaac gcaaaaaggc catccgtcag gatggccttc tgcttaattt 60
gatgcctggc agtttatggc gggcgtcctg cccgccaccc tccgggccgt tgcttcgcaa 120
cgttcaaatc cgctcccggc ggatttgtcc tactcaggag agcgttcacc gacaaacaac 180
agataaaacg aaaggcccag tctttcgact gagcctttcg ttttatttga tgcctggcag 240
ttccctactc tcgcatgggg agaccccaca ctaccatcgg cgctacggcg tttcacttct 300
gagttcggca tggggtcagg tgggaccacc gcgctactgc cgccaggcaa a 351
Claims (5)
1.一种测定至少一种影响使用细胞进行物质生产的代谢流量的方法,所述方法包括如下步骤:
1)基于底物到目标产物的生化反应式建立化学计量矩阵,
2)从所有代谢流量中选择与化学计量矩阵自由度相同数量的独立代谢流量作为自由流量,
3)建立足够数量的自由流量的随机组合进行统计分析,并基于化学计量矩阵从各建立的组合计算代谢流量分布,
4)通过多元统计分析,从计算出的代谢流量分布获得回归方程,其包括最小数量的显示与物质生产相关的自由流量,
5)基于所得回归方程中的系数确定至少一种影响物质生产的代谢流量。
2.根据权利要求1的方法,其中所述统计分析为多元线性回归分析。
3.根据权利要求1或2的方法,其中所述细胞为有能力产生氨基酸、核酸或有机酸的微生物细胞。
4.一种构建具有物质生产能力的细菌菌株的方法,所述方法包括修饰菌株,以至在由权利要求1-3任一项所述的方法测定的影响物质生产的代谢流量中,或在任何属于包括该代谢流量的相同独立代谢流量组的代谢流量中,当代谢流量显示与物质生产正相关时增加相应活性,或当代谢流量显示与物质生产负相关时减弱相应活性,或两者兼有。
5.一种生产物质的方法,所述方法包括将通过权利要求4所述的方法构建的细菌菌株培养于培养基中,以在培养基或细菌细胞中生产和累积物质,并从培养基或细胞中收集物质,其中所述物质为氨基酸、核酸或有机酸。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003202842 | 2003-07-29 | ||
JP202842/2003 | 2003-07-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1856792A CN1856792A (zh) | 2006-11-01 |
CN100520793C true CN100520793C (zh) | 2009-07-29 |
Family
ID=34100609
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200480021509A Expired - Lifetime CN100577799C (zh) | 2003-07-29 | 2004-07-29 | 用苹果酸酶活性减弱的埃希氏菌生产l-赖氨酸或l-苏氨酸的方法 |
CNB2004800272636A Expired - Fee Related CN100520793C (zh) | 2003-07-29 | 2004-07-29 | 影响物质生产的代谢流量的测定方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200480021509A Expired - Lifetime CN100577799C (zh) | 2003-07-29 | 2004-07-29 | 用苹果酸酶活性减弱的埃希氏菌生产l-赖氨酸或l-苏氨酸的方法 |
Country Status (14)
Country | Link |
---|---|
US (3) | US7306933B2 (zh) |
EP (2) | EP1649403A2 (zh) |
JP (2) | JP4665451B2 (zh) |
KR (2) | KR101073370B1 (zh) |
CN (2) | CN100577799C (zh) |
AT (1) | ATE397059T1 (zh) |
BR (2) | BRPI0413030A (zh) |
DE (1) | DE602004014158D1 (zh) |
DK (1) | DK1651758T3 (zh) |
ES (1) | ES2305849T3 (zh) |
PL (1) | PL1651758T3 (zh) |
RU (1) | RU2337140C2 (zh) |
WO (2) | WO2005010794A2 (zh) |
ZA (1) | ZA200510144B (zh) |
Families Citing this family (160)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2000230762A1 (en) | 2000-01-21 | 2001-07-31 | Ajinomoto Co. Inc. | Process for producing l-lysine |
BR0304860A (pt) * | 2002-11-11 | 2004-08-31 | Ajinomoto Kk | Método para produzir uma substância alvo pela utilização de uma-bactéria pertencente ao gênero escherichia |
US7629142B2 (en) | 2004-01-30 | 2009-12-08 | Ajinomoto Co., Inc. | L-amino acid-producing microorganism and method for producing L-amino acid |
JP4802507B2 (ja) * | 2004-02-05 | 2011-10-26 | 味の素株式会社 | 同位体で標識された基質を用いた細胞内代謝フラックスの解析方法 |
US8510054B2 (en) | 2004-02-05 | 2013-08-13 | Ajinomoto Co., Inc. | Intracellular metabolic flux analysis method using substrate labeled with isotope |
JP4654592B2 (ja) * | 2004-04-02 | 2011-03-23 | 味の素株式会社 | 代謝フラックスの決定方法 |
MX2007004166A (es) | 2004-10-07 | 2007-10-23 | Ajinomoto Kk | Proceso para producir una sustancia basica. |
US7915018B2 (en) * | 2004-10-22 | 2011-03-29 | Ajinomoto Co., Inc. | Method for producing L-amino acids using bacteria of the Enterobacteriaceae family |
WO2007013639A1 (en) | 2005-07-25 | 2007-02-01 | Ajinomoto Co., Inc. | A METHOD FOR PRODUCING AN L-AMINO ACID USING A BACTERIUM OF THE ENTEROBACTERIACEAE FAMILY WITH ATTENUATED EXPRESSION OF THE cpxR GENE |
WO2007017710A1 (en) | 2005-08-11 | 2007-02-15 | Metabolic Explorer | Process for the preparation of aspartate and derived amino acids like lysine, threonine, isoleucine, methionine, homoserine, or valine employing a microorganism with enhanced isocitrate lyase and/or malate synthase expression |
US8977530B2 (en) | 2005-09-15 | 2015-03-10 | Korea Advanced Institute Of Science And Technology | Method for identifying genes for enhancing the production of useful substances |
JP2007117082A (ja) * | 2005-09-27 | 2007-05-17 | Ajinomoto Co Inc | L−アミノ酸生産菌及びl−アミノ酸の製造法 |
WO2007037459A1 (en) | 2005-09-27 | 2007-04-05 | Ajinomoto Co., Inc. | An l-amino acid-producing bacterium and a method for producing l-amino acids |
EP1929029A1 (en) | 2005-09-27 | 2008-06-11 | Ajinomoto Co., Inc. | An l-amino acid-producing bacterium and a method for producing l-amino acids |
JP2007185184A (ja) * | 2005-12-16 | 2007-07-26 | Ajinomoto Co Inc | L−アミノ酸生産菌及びl−アミノ酸の製造法 |
EP1979486B1 (en) | 2006-01-30 | 2013-04-17 | Ajinomoto Co., Inc. | L-amino acid producing bacterium and method of producing l-amino acid |
JP2009095237A (ja) * | 2006-02-02 | 2009-05-07 | Ajinomoto Co Inc | L−アミノ酸の製造法 |
JP2009118740A (ja) | 2006-03-03 | 2009-06-04 | Ajinomoto Co Inc | L−アミノ酸の製造法 |
EP2351830B1 (en) | 2006-03-23 | 2014-04-23 | Ajinomoto Co., Inc. | A method for producing an L-amino acid using bacterium of the Enterobacteriaceae family with attenuated expression of a gene coding for small RNA |
RU2338784C2 (ru) * | 2006-03-24 | 2008-11-20 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) | Новая альдолаза, днк, кодирующая альдолазу, клетки, трансформированные днк, способ получения альдолазы и способ получения 4-гидрокси-l-изолейцина (варианты) |
JP2009060791A (ja) * | 2006-03-30 | 2009-03-26 | Ajinomoto Co Inc | L−アミノ酸生産菌及びl−アミノ酸の製造法 |
JP2009165355A (ja) * | 2006-04-28 | 2009-07-30 | Ajinomoto Co Inc | L−アミノ酸を生産する微生物及びl−アミノ酸の製造法 |
KR100727053B1 (ko) * | 2006-05-04 | 2007-06-12 | 한국과학기술원 | 대사산물들의 플럭스 섬 프로파일링을 이용한 생물개량방법 |
JP5407858B2 (ja) * | 2006-07-19 | 2014-02-05 | 味の素株式会社 | 腸内細菌科の細菌を用いたl−アミノ酸の製造方法 |
JP2010017082A (ja) * | 2006-10-10 | 2010-01-28 | Ajinomoto Co Inc | L−アミノ酸の製造法 |
JP2010017081A (ja) * | 2006-10-10 | 2010-01-28 | Ajinomoto Co Inc | L−アミノ酸の製造法 |
EP2094858B1 (en) * | 2006-12-11 | 2015-02-18 | Ajinomoto Co., Inc. | Method for producing an l-amino acid |
RU2006143864A (ru) | 2006-12-12 | 2008-06-20 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) (RU) | СПОСОБ ПОЛУЧЕНИЯ L-АМИНОКИСЛОТ С ИСПОЛЬЗОВАНИЕМ БАКТЕРИИ СЕМЕЙСТВА ENTEROBACTERIACEAE, В КОТОРОЙ ОСЛАБЛЕНА ЭКСПРЕССИЯ ГЕНОВ cynT, cynS, cynX, ИЛИ cynR, ИЛИ ИХ КОМБИНАЦИИ |
JP2010041920A (ja) | 2006-12-19 | 2010-02-25 | Ajinomoto Co Inc | L−アミノ酸の製造法 |
KR100818202B1 (ko) | 2006-12-22 | 2008-03-31 | 한국과학기술원 | 미생물의 성장에 필수적인 대사산물의 스크리닝 방법 |
RU2006145712A (ru) * | 2006-12-22 | 2008-06-27 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) (RU) | Способ получения l-аминокислот методом ферментации с использованием бактерий, обладающих повышенной способностью к утилизации глицерина |
BRPI0703692B1 (pt) | 2006-12-25 | 2016-12-27 | Ajinomoto Kk | método para se obter os cristais de um hidrocloreto de aminoácido básico compreendendo gerar um aminoácido básico usando células microbianas por fermentação em um caldo de fermentação ou por um método enzimático em uma solução de reação de enzima usando as células como catalisadores |
CN101627110B (zh) | 2007-01-22 | 2014-08-13 | 味之素株式会社 | 生产l-氨基酸的微生物和l-氨基酸的生产方法 |
JP2010088301A (ja) * | 2007-02-01 | 2010-04-22 | Ajinomoto Co Inc | L−アミノ酸の製造法 |
JP2010110216A (ja) * | 2007-02-20 | 2010-05-20 | Ajinomoto Co Inc | L−アミノ酸または核酸の製造方法 |
JP2010110217A (ja) | 2007-02-22 | 2010-05-20 | Ajinomoto Co Inc | L−アミノ酸生産菌及びl−アミノ酸の製造法 |
JP2010130899A (ja) | 2007-03-14 | 2010-06-17 | Ajinomoto Co Inc | L−グルタミン酸系アミノ酸生産微生物及びアミノ酸の製造法 |
EP2149608A4 (en) | 2007-04-16 | 2013-02-20 | Ajinomoto Kk | PROCESS FOR PREPARING AN ORGANIC ACID |
EP2147970B1 (en) | 2007-04-17 | 2014-12-31 | Ajinomoto Co., Inc. | A method for producing an acidic substance having a carboxyl group |
JP2010226956A (ja) * | 2007-07-23 | 2010-10-14 | Ajinomoto Co Inc | L−リジンの製造法 |
RU2395579C2 (ru) * | 2007-12-21 | 2010-07-27 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) | СПОСОБ ПОЛУЧЕНИЯ L-АМИНОКИСЛОТЫ С ИСПОЛЬЗОВАНИЕМ БАКТЕРИИ, ПРИНАДЛЕЖАЩЕЙ К РОДУ Escherichia |
JP2010263790A (ja) * | 2007-09-04 | 2010-11-25 | Ajinomoto Co Inc | アミノ酸生産微生物及びアミノ酸の製造法 |
BRPI0816429A2 (pt) | 2007-09-04 | 2019-09-24 | Ajinomoto Kk | microorganismo, e, método para a produção de um l-aminoácido. |
RU2396336C2 (ru) | 2007-09-27 | 2010-08-10 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) | СПОСОБ ПОЛУЧЕНИЯ АМИНОКИСЛОТ С ИСПОЛЬЗОВАНИЕМ БАКТЕРИИ, ПРИНАДЛЕЖАЩЕЙ К РОДУ Escherichia |
JP2010226957A (ja) * | 2007-10-17 | 2010-10-14 | Ajinomoto Co Inc | L−アミノ酸の製造法 |
EP2241630B1 (en) | 2007-12-06 | 2016-06-01 | Ajinomoto Co., Inc. | A method for producing an organic acid |
JP2011067095A (ja) | 2008-01-10 | 2011-04-07 | Ajinomoto Co Inc | 発酵法による目的物質の製造法 |
KR20100120663A (ko) | 2008-01-23 | 2010-11-16 | 아지노모토 가부시키가이샤 | L-아미노산의 제조법 |
RU2008105793A (ru) | 2008-02-19 | 2009-08-27 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) (RU) | Способ конструирования оперонов, содержащих трансляционно сопряженные гены, бактерия, содержащая такой оперон, способ продукции полезного метаболита и способ мониторинга экспрессии гена |
EP2246420B1 (en) | 2008-02-21 | 2014-12-31 | Ajinomoto Co., Inc. | L-cysteine-producing bacterium, and method for production of l-cysteine |
BRPI0907542A2 (pt) | 2008-02-25 | 2015-07-28 | Ajinomoto Kk | Método para produzir ácido 5'-guanílico, e, microrganismo com uma capacidade de converter ácido inosínico em ácido 5'-guanílico |
ES2510865T3 (es) | 2008-03-03 | 2014-10-21 | Global Bio-Chem Technology Group Company Limited | Microorganismo recombinante y procedimiento para producir L-lisina |
JP5332237B2 (ja) | 2008-03-06 | 2013-11-06 | 味の素株式会社 | L−システイン生産菌及びl−システインの製造法 |
JP2011167071A (ja) * | 2008-05-22 | 2011-09-01 | Ajinomoto Co Inc | L−アミノ酸の製造法 |
WO2010027022A1 (ja) | 2008-09-05 | 2010-03-11 | 味の素株式会社 | L-アミノ酸生産菌及びl-アミノ酸の製造法 |
EP2336347B1 (en) | 2008-09-08 | 2017-03-15 | Ajinomoto Co., Inc. | An l-amino acid-producing microorganism and a method for producing an l-amino acid |
JP2012029565A (ja) | 2008-11-27 | 2012-02-16 | Ajinomoto Co Inc | L−アミノ酸の製造法 |
JP2010142200A (ja) | 2008-12-22 | 2010-07-01 | Ajinomoto Co Inc | L−リジンの製造法 |
WO2010084995A2 (en) | 2009-01-23 | 2010-07-29 | Ajinomoto Co.,Inc. | A method for producing an l-amino acid |
JP5521347B2 (ja) | 2009-02-16 | 2014-06-11 | 味の素株式会社 | L−アミノ酸生産菌及びl−アミノ酸の製造法 |
JP5359409B2 (ja) | 2009-03-12 | 2013-12-04 | 味の素株式会社 | L−システイン生産菌及びl−システインの製造法 |
CN102471790B (zh) | 2009-07-29 | 2014-10-29 | 味之素株式会社 | 产生l-氨基酸的方法 |
JP2012196144A (ja) | 2009-08-03 | 2012-10-18 | Ajinomoto Co Inc | ビブリオ属細菌を用いたl−リジンの製造法 |
JP5636648B2 (ja) | 2009-08-10 | 2014-12-10 | 味の素株式会社 | 5’−グアニル酸の製造法 |
WO2011021717A2 (en) | 2009-08-21 | 2011-02-24 | Ajinomoto Co.,Inc. | Method for producing hydroxylated amino acids |
JP2012223092A (ja) | 2009-08-28 | 2012-11-15 | Ajinomoto Co Inc | L−アミノ酸の製造法 |
WO2011034263A1 (ko) * | 2009-09-18 | 2011-03-24 | 한국과학기술원 | 필수 대사산물을 이용한 병원성 미생물의 약물 표적 예측 방법 |
RU2009136544A (ru) | 2009-10-05 | 2011-04-10 | Закрытое акционерное общество "Научно-исследовательский институт "Аджиномото-Генетика" (ЗАО АГРИ) (RU) | Способ получения l-цистеина с использованием бактерии семейства enterobacteriaceae |
JP2013013329A (ja) | 2009-11-06 | 2013-01-24 | Ajinomoto Co Inc | L−アミノ酸の製造法 |
WO2011065469A1 (ja) | 2009-11-30 | 2011-06-03 | 味の素株式会社 | L-システイン生産菌及びl-システインの製造法 |
RU2460793C2 (ru) | 2010-01-15 | 2012-09-10 | Закрытое акционерное общество "Научно-исследовательский институт "Аджиномото-Генетика" (ЗАО АГРИ) | Способ получения l-аминокислот с использованием бактерий семейства enterobacteriaceae |
RU2010101135A (ru) | 2010-01-15 | 2011-07-20 | Закрытое акционерное общество "Научно-исследовательский институт "Аджиномото-Генетика" (ЗАО АГРИ) (RU) | Бактерия семейства enterobacteriaceae - продуцент l-аспартата или метаболитов, производных l-аспартата, и способ получения l-аспартата или метаболитов, производных l-аспартата |
JP2013074795A (ja) | 2010-02-08 | 2013-04-25 | Ajinomoto Co Inc | 変異型rpsA遺伝子及びL−アミノ酸の製造法 |
WO2011100601A1 (en) | 2010-02-11 | 2011-08-18 | Metabolix, Inc. | Process for gamma-butyrolactone production |
RU2471868C2 (ru) | 2010-02-18 | 2013-01-10 | Закрытое акционерное общество "Научно-исследовательский институт "Аджиномото-Генетика" (ЗАО АГРИ) | Мутантная аденилатциклаза, днк, кодирующая ее, бактерия семейства enterobacteriaceae, содержащая указанную днк, и способ получения l-аминокислот |
RU2471870C2 (ru) | 2010-06-03 | 2013-01-10 | Закрытое акционерное общество "Научно-исследовательский институт "Аджиномото-Генетика" (ЗАО АГРИ) | СПОСОБ ПОЛУЧЕНИЯ L-АРГИНИНА И L-ЦИТРУЛЛИНА С ИСПОЛЬЗОВАНИЕМ БАКТЕРИИ СЕМЕЙСТВА ENTEROBACTERIACEAE, В КОТОРОЙ ОСЛАБЛЕНА ЭКСПРЕССИЯ ГЕНА pepA |
RU2010122646A (ru) | 2010-06-03 | 2011-12-10 | Закрытое акционерное общество "Научно-исследовательский институт "Аджиномото-Генетика" (ЗАО АГРИ) (RU) | Способ получения l-аминокислоты с использованием бактерии семейства enterobacteriaceae, в которой ослаблена экспрессия генов, кодирующих транспортер лизина/аргинина/орнитина |
RU2482188C2 (ru) | 2010-07-21 | 2013-05-20 | Закрытое акционерное общество "Научно-исследовательский институт "Аджиномото-Генетика" (ЗАО АГРИ) | СПОСОБ ПОЛУЧЕНИЯ L-АРГИНИНА С ИСПОЛЬЗОВАНИЕМ БАКТЕРИЙ РОДА Escherichia, В КОТОРОЙ ИНАКТИВИРОВАН ОПЕРОН astCADBE |
RU2501858C2 (ru) | 2010-07-21 | 2013-12-20 | Закрытое акционерное общество "Научно-исследовательский институт "Аджиномото-Генетика" (ЗАО АГРИ) | СПОСОБ ПОЛУЧЕНИЯ L-АМИНОКИСЛОТЫ С ИСПОЛЬЗОВАНИЕМ БАКТЕРИИ СЕМЕЙСТВА Enterobacteriaceae |
WO2012036151A1 (ja) | 2010-09-14 | 2012-03-22 | 味の素株式会社 | 含硫アミノ酸生産菌及び含硫アミノ酸の製造法 |
JP2014036576A (ja) | 2010-12-10 | 2014-02-27 | Ajinomoto Co Inc | L−アミノ酸の製造法 |
JP2014087259A (ja) | 2011-02-22 | 2014-05-15 | Ajinomoto Co Inc | L−システイン生産菌及びl−システインの製造法 |
JP6020443B2 (ja) | 2011-04-01 | 2016-11-02 | 味の素株式会社 | L−システインの製造法 |
JP2014131487A (ja) | 2011-04-18 | 2014-07-17 | Ajinomoto Co Inc | L−システインの製造法 |
US20140114082A1 (en) | 2011-06-08 | 2014-04-24 | Metabolix, Inc. | Biorefinery Process For THF Production |
EP2742143A1 (en) | 2011-08-10 | 2014-06-18 | Metabolix, Inc. | Post process purification for gamma-butyrolactone production |
RU2011134436A (ru) | 2011-08-18 | 2013-10-27 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО "АГРИ") | Способ получения l-аминокислоты с использованием бактерии семейства enterobacteriaceae, обладающей повышенной экспрессией генов каскада образования флагелл и клеточной подвижности |
WO2013051685A1 (ja) | 2011-10-07 | 2013-04-11 | 味の素株式会社 | 変異型γ-グルタミルトランスフェラーゼ、及び、γ-グルタミルバリルグリシン又はその塩の製造法 |
JP2015013812A (ja) | 2011-11-01 | 2015-01-22 | 味の素株式会社 | 植物ウイルスの感染抑制剤およびそれを用いた植物ウイルス感染抑制方法 |
JP6136930B2 (ja) | 2011-11-02 | 2017-05-31 | 味の素株式会社 | タンパク質の分泌生産法 |
KR20140091742A (ko) | 2011-11-11 | 2014-07-22 | 아지노모토 가부시키가이샤 | 발효법에 의한 목적 물질의 제조법 |
CN104540959B (zh) | 2012-08-10 | 2018-11-13 | 味之素株式会社 | γ-谷氨酰缬氨酰甘氨酸晶体的制备方法 |
RU2550269C2 (ru) | 2012-08-17 | 2015-05-10 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО "АГРИ") | СПОСОБ ПОЛУЧЕНИЯ L-АРГИНИНА С ИСПОЛЬЗОВАНИЕМ БАКТЕРИИ СЕМЕЙСТВА Enterobacteriaceae, СОДЕРЖАЩЕЙ N-АЦЕТИЛОРНИТИНДЕАЦЕТИЛАЗУ С НАРУШЕННОЙ АКТИВНОСТЬЮ |
RU2013118637A (ru) | 2013-04-23 | 2014-10-27 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО "АГРИ") | СПОСОБ ПОЛУЧЕНИЯ L-АМИНОКИСЛОТ С ИСПОЛЬЗОВАНИЕМ БАКТЕРИИ СЕМЕЙСТВА ENTEROBACTERIACEAE, В КОТОРОЙ РАЗРЕГУЛИРОВАН ГЕН yjjK |
EP2868745B1 (en) | 2013-05-13 | 2017-06-21 | Ajinomoto Co., Inc. | Method for manufacturing an L-amino acid |
JP2016165225A (ja) | 2013-07-09 | 2016-09-15 | 味の素株式会社 | 有用物質の製造方法 |
RU2013140115A (ru) | 2013-08-30 | 2015-03-10 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО "АГРИ") | СПОСОБ ПОЛУЧЕНИЯ L-АМИНОКИСЛОТ С ИСПОЛЬЗОВАНИЕМ БАКТЕРИИ СЕМЕЙСТВА Enterobacteriaceae, В КОТОРОЙ НАРУШЕНА ЭКСПРЕССИЯ КЛАСТЕРА ГЕНОВ znuACB |
JP2016192903A (ja) | 2013-09-17 | 2016-11-17 | 味の素株式会社 | 海藻由来バイオマスからのl−アミノ酸の製造方法 |
EP3054005B1 (en) | 2013-10-02 | 2019-11-20 | Ajinomoto Co., Inc. | Heparosan-producing bacterium and heparosan manufacturing method |
BR112016007286B1 (pt) | 2013-10-02 | 2021-07-20 | Ajinomoto Co., Inc | Métodos de controle de amônia e para produção de uma substância alvo, e, aparelho para controle de amônia |
RU2013144250A (ru) | 2013-10-02 | 2015-04-10 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО "АГРИ") | СПОСОБ ПОЛУЧЕНИЯ L-АМИНОКИСЛОТ С ИСПОЛЬЗОВАНИЕМ БАКТЕРИИ СЕМЕЙСТВА Enterobacteriaceae, В КОТОРОЙ ОСЛАБЛЕНА ЭКСПРЕССИЯ ГЕНА, КОДИРУЮЩЕГО ФОСФАТНЫЙ ТРАНСПОРТЕР |
PL2886651T3 (pl) | 2013-10-21 | 2018-11-30 | Ajinomoto Co., Inc. | Sposób wytwarzania l-aminokwasu |
WO2015060391A1 (ja) | 2013-10-23 | 2015-04-30 | 味の素株式会社 | 目的物質の製造法 |
EP3101130B1 (en) | 2014-01-31 | 2020-05-06 | Ajinomoto Co., Inc. | Mutant glutamate-cysteine ligase and method for manufacturing gamma-glutamyl-valyl-glycine |
RU2014105547A (ru) | 2014-02-14 | 2015-08-20 | Адзиномото Ко., Инк. | СПОСОБ ПОЛУЧЕНИЯ L-АМИНОКИСЛОТ С ИСПОЛЬЗОВАНИЕМ БАКТЕРИИ СЕМЕЙСТВА ENTEROBACTERIACEAE, ИМЕЮЩЕЙ СВЕРХЭКСПРЕССИРУЕМЫЙ ГЕН yajL |
JP2017216881A (ja) | 2014-12-26 | 2017-12-14 | 味の素株式会社 | ジカルボン酸の製造方法 |
CN104878034B (zh) * | 2015-04-17 | 2018-04-27 | 上海工业生物技术研发中心 | L-赖氨酸基因工程生产菌 |
AU2016265751A1 (en) | 2015-05-19 | 2017-12-14 | Lucite International Uk Limited | Process for the biological production of methacrylic acid and derivatives thereof |
RU2015120052A (ru) | 2015-05-28 | 2016-12-20 | Аджиномото Ко., Инк. | Способ получения L-аминокислоты с использованием бактерии семейства Enterobacteriaceae, в которой ослаблена экспрессия гена gshA |
KR101694811B1 (ko) * | 2015-07-15 | 2017-01-13 | 대상 주식회사 | 말산 효소 또는 젖산 탈수소효소의 불활성화에 의한 아미노산 고생산능 변이 균주 |
CN105018413B (zh) * | 2015-08-28 | 2018-04-03 | 中国科学院重庆绿色智能技术研究院 | 一种浮游植物细胞模型及其构建和应用 |
WO2017073701A2 (en) | 2015-10-27 | 2017-05-04 | Ajinomoto Co., Inc. | Method for producing aldehyde |
JP6623690B2 (ja) | 2015-10-30 | 2019-12-25 | 味の素株式会社 | グルタミン酸系l−アミノ酸の製造法 |
JP7107225B2 (ja) | 2016-01-12 | 2022-07-27 | 味の素株式会社 | ベンズアルデヒドの製造方法 |
CN109121422B (zh) | 2016-02-25 | 2021-12-21 | 味之素株式会社 | 使用过表达编码铁输出蛋白基因的肠杆菌科的细菌生产l-氨基酸的方法 |
AU2017347016B2 (en) | 2016-10-21 | 2021-09-23 | Ajinomoto Co., Inc. | Secretory production method for protein |
EP3530747A4 (en) | 2016-10-21 | 2020-07-22 | Ajinomoto Co., Inc. | SECRETORY PROTEIN PRODUCTION PROCESS |
JP2019536449A (ja) | 2016-10-26 | 2019-12-19 | 味の素株式会社 | 目的物質の製造方法 |
WO2018079686A1 (en) | 2016-10-26 | 2018-05-03 | Ajinomoto Co., Inc. | Method for producing l-methionine or metabolites requiring s-adenosylmethionine for synthesis |
JP7063332B2 (ja) | 2016-10-26 | 2022-05-09 | 味の素株式会社 | 目的物質の製造方法 |
WO2018079685A1 (en) | 2016-10-26 | 2018-05-03 | Ajinomoto Co., Inc. | Method for producing objective substance |
WO2018079687A1 (en) | 2016-10-26 | 2018-05-03 | Ajinomoto Co., Inc. | Method for producing objective substance |
WO2018079705A1 (en) | 2016-10-27 | 2018-05-03 | Ajinomoto Co., Inc. | Method for producing aldehyde |
GB201619827D0 (en) | 2016-11-23 | 2017-01-04 | Lucite Int Uk Ltd | Process for the production of methyl methacrylate |
CN118773233A (zh) | 2017-03-28 | 2024-10-15 | 味之素株式会社 | 生产rna的方法 |
JP7066977B2 (ja) | 2017-04-03 | 2022-05-16 | 味の素株式会社 | L-アミノ酸の製造法 |
US10858676B2 (en) | 2017-05-22 | 2020-12-08 | Ajinomoto Co., Inc. | Method for producing objective substance |
WO2019059404A1 (ja) | 2017-09-25 | 2019-03-28 | 味の素株式会社 | タンパク質の製造法および二糖の製造法 |
US11680279B2 (en) | 2017-11-29 | 2023-06-20 | Ajinomoto Co., Inc. | Method for producing objective substance |
KR101947945B1 (ko) | 2018-01-25 | 2019-02-13 | 씨제이제일제당 (주) | L-아미노산을 생산하는 코리네박테리움 속 미생물 및 이를 이용한 l-아미노산의 생산방법 |
CN111757673A (zh) | 2018-02-20 | 2020-10-09 | 味之素株式会社 | 诱导rna沉默的方法 |
JP7124338B2 (ja) | 2018-02-27 | 2022-08-24 | 味の素株式会社 | 変異型グルタチオン合成酵素、及び、γ-グルタミルバリルグリシンの製造法 |
TW202117002A (zh) | 2018-03-27 | 2021-05-01 | 南韓商Cj第一製糖股份有限公司 | 具有增強的甘胺酸生產力的微生物及使用該微生物製造醱酵組成物的方法 |
WO2019203368A1 (ja) | 2018-04-20 | 2019-10-24 | 味の素株式会社 | タンパク質の分泌生産法 |
WO2019212052A1 (en) | 2018-05-04 | 2019-11-07 | Ajinomoto Co., Inc. | METHOD FOR PRODUCING L-METHIONINE USING A BACTERIUM OF THE GENUS Pantoea |
JP7447810B2 (ja) | 2018-05-23 | 2024-03-12 | 味の素株式会社 | 腸内細菌科を用いたトリペプチドγ-GLU-VAL-GLYの製造方法 |
WO2020027251A1 (en) | 2018-08-03 | 2020-02-06 | Ajinomoto Co., Inc. | Method for producing objective substance |
WO2020071538A1 (en) | 2018-10-05 | 2020-04-09 | Ajinomoto Co., Inc. | Method for producing target substance by bacterial fermentation |
WO2020085511A1 (ja) | 2018-10-25 | 2020-04-30 | 味の素株式会社 | タンパク質の分泌生産法 |
BR112021011882A2 (pt) | 2018-12-27 | 2021-09-08 | Ajinomoto Co., Inc. | Método para produzir um l-aminoácido básico |
KR102276219B1 (ko) | 2019-02-15 | 2021-07-12 | 씨제이제일제당 (주) | 생물반응기의 운전 조건을 결정하는 장치 및 방법 |
BR112021014194A2 (pt) | 2019-02-22 | 2021-12-28 | Ajinomoto Kk | Método para a produção de um l-aminoácido |
BR112021019284A2 (pt) | 2019-03-29 | 2022-02-01 | Ajinomoto Kk | Métodos para produzir alolactose e para produzir um indutor de expressão gênica |
JP7524909B2 (ja) | 2019-04-05 | 2024-07-30 | 味の素株式会社 | L-アミノ酸の製造方法 |
WO2020226087A1 (ja) | 2019-05-08 | 2020-11-12 | 味の素株式会社 | バニリンの製造方法 |
KR102221040B1 (ko) | 2019-05-09 | 2021-03-03 | 씨제이제일제당 주식회사 | L-아미노산을 생산하는 미생물 및 이를 이용한 l-아미노산을 생산하는 방법 |
KR102153534B1 (ko) | 2019-09-02 | 2020-09-09 | 씨제이제일제당 주식회사 | 신규한 프로모터 및 이를 이용한 아미노산 생산 방법 |
JP7655312B2 (ja) | 2019-09-25 | 2025-04-02 | 味の素株式会社 | 細菌の発酵によるl-アミノ酸の製造方法 |
WO2021085405A1 (ja) | 2019-10-28 | 2021-05-06 | 味の素株式会社 | ベンズアルデヒドの製造方法 |
MX2023002783A (es) | 2020-09-09 | 2023-03-15 | Cj Cheiljedang Corp | Un microorganismo recombinante para producir acido l-glutamico y un metodo para producir acido l-glutamico utilizando el mismo. |
EP4239070A1 (en) | 2020-10-28 | 2023-09-06 | Ajinomoto Co., Inc. | Method of producing l-amino acid |
KR102527096B1 (ko) | 2021-02-01 | 2023-04-28 | 씨제이제일제당 주식회사 | 프리페네이트 탈수 효소 (Prephenate dehydratase) 변이체 및 이를 이용한 분지쇄 아미노산 생산 방법 |
KR102649245B1 (ko) | 2021-03-08 | 2024-03-21 | 씨제이제일제당 주식회사 | L-아미노산을 생산하는 코리네박테리움 속 미생물 및 이를 이용한 l-아미노산의 생산방법 |
KR102339264B1 (ko) | 2021-05-07 | 2021-12-14 | 씨제이제일제당 주식회사 | 신규 프로모터 및 이의 용도 |
KR102339271B1 (ko) | 2021-05-07 | 2021-12-14 | 씨제이제일제당 주식회사 | 신규 프로모터 및 이의 용도 |
CN117642511A (zh) | 2021-07-07 | 2024-03-01 | 味之素株式会社 | 含非天然氨基酸的蛋白质的分泌生产方法 |
WO2023195475A1 (ja) | 2022-04-04 | 2023-10-12 | 味の素株式会社 | 寄生植物を防除する方法 |
EP4509613A1 (en) | 2022-04-15 | 2025-02-19 | Ajinomoto Co., Inc. | Method for producing cultured meat |
GB2621337A (en) | 2022-08-08 | 2024-02-14 | Mitsubishi Chemical Uk Ltd | Process for the biological production of methacrylic acid and derivatives thereof |
US20240117393A1 (en) | 2022-09-30 | 2024-04-11 | Ajinomoto Co., Inc. | Method for producing l-amino acid |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5976843A (en) * | 1992-04-22 | 1999-11-02 | Ajinomoto Co., Inc. | Bacterial strain of Escherichia coli BKIIM B-3996 as the producer of L-threonine |
US5175107A (en) * | 1988-10-25 | 1992-12-29 | Ajinomoto Co., Inc. | Bacterial strain of escherichia coli bkiim b-3996 as the producer of l-threonine |
US6132999A (en) * | 1992-09-21 | 2000-10-17 | Ajinomoto Co., Inc. | L-threonine-producing microbacteria and a method for the production of L-threonine |
JP2817400B2 (ja) | 1993-10-28 | 1998-10-30 | 味の素株式会社 | 物質の製造法 |
WO2000046405A2 (en) | 1999-02-02 | 2000-08-10 | Bernhard Palsson | Methods for identifying drug targets based on genomic sequence data |
FR2796080B1 (fr) * | 1999-06-18 | 2003-08-08 | Orsan | Procede de production de la l-lysine par surexpression de l'enzyme malique |
US6830903B1 (en) * | 1999-07-23 | 2004-12-14 | Archer-Daniels-Midland Company | Methods for producing L-amino acids using a corynebacterium glutamicum with a disrupted pgi gene |
BR0016656A (pt) * | 1999-12-24 | 2002-11-05 | Ajinomoto Kk | Bactéria corineforme, método para produzir um l-aminoácido, e, dna |
JP4380029B2 (ja) * | 2000-07-05 | 2009-12-09 | 味の素株式会社 | 微生物を利用した物質の製造法 |
US20020155556A1 (en) * | 2000-12-22 | 2002-10-24 | Ajinomoto Co., Inc | Method of producing target substance by fermentation |
US7711490B2 (en) | 2001-01-10 | 2010-05-04 | The Penn State Research Foundation | Method and system for modeling cellular metabolism |
JP2002209596A (ja) * | 2001-01-19 | 2002-07-30 | Ajinomoto Co Inc | L−アミノ酸の製造法 |
US7127379B2 (en) | 2001-01-31 | 2006-10-24 | The Regents Of The University Of California | Method for the evolutionary design of biochemical reaction networks |
EP1381860A4 (en) * | 2001-03-01 | 2008-10-15 | Univ California | MODELS AND METHOD FOR DETERMINING SYSTEMIC PROPERTIES OF REGULATED RESPONSE NETWORKS |
JP2002330763A (ja) * | 2001-05-02 | 2002-11-19 | Ajinomoto Co Inc | 発酵法による目的物質の製造法 |
IL160151A0 (en) | 2001-08-10 | 2004-07-25 | Nat Public Health Inst | Identification of a dna variant associated with adult type hypolactasia |
WO2003029425A2 (en) * | 2001-10-01 | 2003-04-10 | Diversa Corporation | Whole cell engineering using real-time metabolic flux analysis |
JP2003250544A (ja) * | 2002-03-04 | 2003-09-09 | National Institute Of Technology & Evaluation | タンパク質の性質を改変する方法 |
DE10224088A1 (de) * | 2002-05-31 | 2003-12-11 | Degussa | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung coryneformer Bakterien die ein abgeschwächtes mez-Gen enthalten |
US6911332B2 (en) * | 2002-06-12 | 2005-06-28 | Ajinomoto Co., Inc. | Isolated polynucleotides encoding d-arabino-3-hexulose-6-phosphate synthases from Methylophilus methylotrophus |
AU2003205041A1 (en) * | 2002-07-12 | 2004-01-29 | Ajinomoto Co., Inc. | Method for producing target substance by fermentation |
BR0304860A (pt) * | 2002-11-11 | 2004-08-31 | Ajinomoto Kk | Método para produzir uma substância alvo pela utilização de uma-bactéria pertencente ao gênero escherichia |
US7029893B2 (en) * | 2003-02-28 | 2006-04-18 | Ajinomoto Co., Inc. | Polynucleotides encoding polypeptides involved in amino acid biosynthesis in methylophilus methylotrophus |
US20060019356A1 (en) * | 2003-02-28 | 2006-01-26 | Yoshihiro Usuda | Polynucleotides encoding polypeptides involved in intermediates metabolism of the central metabolic pathway in Methylophilus methylotrophus |
US7060475B2 (en) * | 2003-02-28 | 2006-06-13 | Ajinomoto Co., Inc. | Polynucleotides encoding polypeptides involved in intermediates metabolism of central metabolic pathway in methylophilus methylotrophus |
US7026149B2 (en) * | 2003-02-28 | 2006-04-11 | Ajinomoto Co., Inc. | Polynucleotides encoding polypeptides involved in the stress response to environmental changes in Methylophilus methylotrophus |
US7468262B2 (en) * | 2003-05-16 | 2008-12-23 | Ajinomoto Co., Inc. | Polynucleotides encoding useful polypeptides in corynebacterium glutamicum ssp. lactofermentum |
JP4380305B2 (ja) | 2003-11-21 | 2009-12-09 | 味の素株式会社 | 発酵法によるl−アミノ酸の製造法 |
US7629142B2 (en) * | 2004-01-30 | 2009-12-08 | Ajinomoto Co., Inc. | L-amino acid-producing microorganism and method for producing L-amino acid |
US7915018B2 (en) | 2004-10-22 | 2011-03-29 | Ajinomoto Co., Inc. | Method for producing L-amino acids using bacteria of the Enterobacteriaceae family |
WO2006078039A1 (en) | 2005-01-18 | 2006-07-27 | Ajinomoto Co., Inc. | L-amino acid producing microorganism and a method for producing l-amino acid |
US20070004014A1 (en) | 2005-06-29 | 2007-01-04 | Yuichiro Tsuji | Method for producing l-threonine |
-
2004
- 2004-07-29 CN CN200480021509A patent/CN100577799C/zh not_active Expired - Lifetime
- 2004-07-29 DE DE602004014158T patent/DE602004014158D1/de not_active Expired - Lifetime
- 2004-07-29 ES ES04771247T patent/ES2305849T3/es not_active Expired - Lifetime
- 2004-07-29 PL PL04771247T patent/PL1651758T3/pl unknown
- 2004-07-29 WO PCT/JP2004/011212 patent/WO2005010794A2/en not_active Application Discontinuation
- 2004-07-29 KR KR1020067002048A patent/KR101073370B1/ko not_active Expired - Fee Related
- 2004-07-29 RU RU2006101328/13A patent/RU2337140C2/ru active
- 2004-07-29 WO PCT/JP2004/011220 patent/WO2005010175A1/en active IP Right Grant
- 2004-07-29 DK DK04771247T patent/DK1651758T3/da active
- 2004-07-29 EP EP04771239A patent/EP1649403A2/en not_active Withdrawn
- 2004-07-29 JP JP2004222088A patent/JP4665451B2/ja not_active Expired - Lifetime
- 2004-07-29 BR BRPI0413030-8A patent/BRPI0413030A/pt not_active IP Right Cessation
- 2004-07-29 JP JP2004221708A patent/JP4894134B2/ja not_active Expired - Fee Related
- 2004-07-29 ZA ZA200510144A patent/ZA200510144B/xx unknown
- 2004-07-29 EP EP04771247A patent/EP1651758B1/en not_active Expired - Lifetime
- 2004-07-29 CN CNB2004800272636A patent/CN100520793C/zh not_active Expired - Fee Related
- 2004-07-29 BR BRPI0413007A patent/BRPI0413007B1/pt active IP Right Grant
- 2004-07-29 AT AT04771247T patent/ATE397059T1/de not_active IP Right Cessation
-
2005
- 2005-12-21 KR KR1020057024543A patent/KR101208480B1/ko not_active Expired - Lifetime
-
2006
- 2006-01-03 US US11/275,437 patent/US7306933B2/en not_active Expired - Lifetime
- 2006-01-24 US US11/337,580 patent/US7809511B2/en active Active
-
2007
- 2007-10-24 US US11/877,726 patent/US8030036B2/en active Active
Non-Patent Citations (5)
Title |
---|
FluxAnalyzer:exploring structure,pathways,and fluxdistributions in metabolic networks on interactive flux maps. Steffen Klamt.Bioinformatics,Oxford University Press 2003,Vol.19 No.2. 2003 |
FluxAnalyzer:exploring structure,pathways,and fluxdistributions in metabolic networks on interactive flux maps. Steffen Klamt.Bioinformatics,Oxford University Press 2003,Vol.19 No.2. 2003 * |
Metabolic Flux Balancing:Basic Concepts,Scientificand Practical Use. Amit Varma and Bernhard O.Palsson.BIO/TECHNOLOGY,Vol.12 . 1994 |
Metabolic Flux Balancing:Basic Concepts,Scientificand Practical Use. Amit Varma and Bernhard O.Palsson.BIO/TECHNOLOGY,Vol.12. 1994 * |
Serine alkaline protease overproduction capacity of Bacilluslicheniformis. Pinar Calik et al.Enzyme and Microbial Technology. 2000 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100520793C (zh) | 影响物质生产的代谢流量的测定方法 | |
EP0796912B9 (en) | Novel lysine decarboxylase gene and process for producing l-lysine | |
JP3473042B2 (ja) | 変異型アスパルトキナーゼ遺伝子 | |
Cocaign-Bousquet et al. | Growth rate-dependent modulation of carbon flux through central metabolism and the kinetic consequences for glucose-limited chemostat cultures of Corynebacterium glutamicum | |
JP6961819B2 (ja) | L−リジンを生産する組換え菌、その構築方法およびl−リジンの生産方法 | |
CA2175042C (en) | Method for production of substances using microorganisms with an increased productivity for nadph | |
Weuster-Botz et al. | Medium optimization by genetic algorithm for continuous production of formate dehydrogenase | |
BRPI0807802B1 (pt) | corynebacteria e método para produzir um produto de fermentação utilizando glicerol | |
JP2001120269A (ja) | 発酵法によるl−リジンの製造法 | |
JPH01187093A (ja) | 発酵法によるl―スレオニンの製造法 | |
JP2003503064A (ja) | 炭素同化の調節 | |
Ramesh | Approaches for improving the production of L-Lysine in Corynebacterium glutamicum | |
CN116875575A (zh) | 一种l-氨基酸脱氢酶突变体及其编码基因、基因工程菌以及在制备l-草铵膦中的应用 | |
JPS58170487A (ja) | 発酵法によるl−リジンの製造法 | |
Мосин | Methylotrophic biomass as 2h-labeled substrate for biosynthesis of inosine | |
Mosin | Methylotrophic biomass as 2H-labeled substrate for biosynthesis of inosine-статья | |
JPH02286091A (ja) | 発酵法によるl―スレオニンの製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090729 |
|
CF01 | Termination of patent right due to non-payment of annual fee |